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ABSTRACT 
Background: Stavudine (d4T) use is associated with the development of 
sensory neuropathy (SN), several mechanisms may underlie d4T-induced 
toxicity, including: 
(1) Inter-patient genetic variability in the genes modulating the 
deoxynucleotide triphosphate (dNTP) pool sizes.  
(2) Variation in intracellular ARV drug concentrations due to genetic 
variation in drug transporters. 
In our study we examined the genetic variation in four stavudine transporter 
genes and seven genes regulating the deoxythymidine triphosphate (dTTP) 
synthesis and their associations with d4T-induced SN or CD4+ T cell count 
or mtDNA copy number. 
Methods: We examined a cohort of HIV-positive South African (SA) adults 
exposed to d4T, including 143 cases with SN and 120 controls without SN.  
26 single nucleotide polymorphisms (SNPs) from the literature were chosen, 
prioritised on being tagSNPs with minor allele frequency >5% in Kenyan 
Luhya (a proxy population for the SA Black population); SNP functional 
effects and suitability for multiplex analysis on the genotyping platform. 
Genotyping was performed using Sequenom mass spectrometry. A qPCR 
assay was used to measure the mtDNA copy number. Association of 
sensory neuropathy, CD4+ T cell count and mtDNA copy number with 
genetic variants was evaluated using PLINK.  
Results: All 26 SNPs were in Hardy-Weinberg equilibrium (HWE) in both the 
cases and controls. SNP rs8187758 of the SLC28A1 transporter gene and 
a 3-SNP haplotype ABCG2 were significantly associated with CD4+ T cell 
count after correction for multiple testing (p = 0.043 and p=0.042 
respectively), but were not significant in multivariate testing. No SNP 
remained significantly associated with SN or mtDNA copy number, after 
correction for multiple testing. 
Conclusion: Variation in genes encoding molecular transporters of d4T may 
influence CD4+ T cell counts after ART. This study presents a positive step 
towards achieving personalized medicine in SA.   
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CHAPTER 1: INTRODUCTION  
1.1 HIV and HAART 
Human Immunodeficiency Virus (HIV) is still a major health threat with over 36.9 million 
people living with HIV, of which 25.8 million are based in sub-Saharan Africa accounting 
for almost 70% of all people living with HIV by the end of 2015 (Joint United National 
Global Fact Sheet, 2015).  However, the introduction of antiretroviral drugs (ARVs) since 
1995 (2003 in South Africa) has caused a decline in the mortality and morbidity rate of 
those living with HIV/AIDS and accordingly the life expectancy of HIV/AIDS patients has 
improved (Brinkman et al., 1999; Menezes et al., 2013). There are six classes of ARVs, 
including nucleoside reverse transcriptase inhibitors (NRTIs), non-reverse nucleoside 
transcriptase inhibitors (NNRTIs), protease inhibitors (PI), integrase inhibitors (INSTI), 
fusion inhibitors, and co-receptor antagonists (Pirmohamed & Back, 2001). A three drug 
combination referred to as highly active antiretroviral therapy (HAART) was introduced 
worldwide in 1996 as a standard course of therapy (Brinkman et al., 1999). The NRTIs 
serve as the backbone of virtually all the ART regimens which usually comprise of two 
NRTIs plus a NNRTI, a PI or INSTI (Marcelin et al., 2014). In South Africa (SA) HAART 
was initiated in 2003 with the SA Government ART roll-out commencing in 2004 
according to the national ART programme (Menezes et al., 2013; National Antiretroviral 
Treatment guidelines SA, 2004; National Consolidated ART Guidelines SA, 2016, Table 
1.1). 
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Table 1.1 South African National First line Antiretroviral Treatment Guidelines 2004-
2016.  
Year Regimen 1a CD4+ T cell count at  treatment initiation  
2004 d4T+ 3TC + EFV Starting at CD4+ T cell counts < 200 cell/mm3 
2010 TDF+ 3TC+ EFV Starting at CD4+ T cell counts < 350 cell/mm3 
2015 TDF+ (FTC or 3TC)+ EFV Starting at CD4+ T cell counts < 500 cell/mm3 
2016 TDF+ (FTC or 3TC)+ EFV Starting at any CD4+ T cell count 
Legend: d4T (stavudine), 3TC (lamivudine), NVP (nevirapine), TDF (tenofovir), EFV 
(efavirenz), FTC (Emtricitabine) and cell/mm3 (cells per millimeter). 
Stavudine-based regimens were the baseline of the South African ART programme for 
approximately six years as part of the first-line public sector HAART, but due to the 
adverse effects of stavudine, since 2010 the South African ART guidelines replaced 
stavudine with tenofovir (TDF) (Menezes et al., 2013). 
 
The use of ART usually successfully reduces  the HIV viral load by halting its replication 
in many individuals and thus boosts CD4+ T-cell recovery which lead to the decrease of 
AIDS associated deaths and diseases (Baker et al., 2008). It has been noted that 15-30% 
of the patients on long-term ART do not respond to the treatment which can result in the 
lack of CD4+ T-cell recovery to normal levels  amidst full suppression of HIV replication;  
these patients are referred to as immunological non-responders (INRs) (Gazzola et al., 
2009).  Several clinical factors have been associated with poor CD4+ T cell recovery after 
ART, including baseline CD4+ T cell count, thymus function, anaemia,  age, advanced 
stage of disease, and co-infections (Hunt et al., 2003; Aiuti and  Mezzarroma, 2006; Baker 
et al., 2008; Muzah et al., 2012;  Massanella et al., 2013).  Immunological non-response,   
or varying levels and rates of CD4+ T cell recovery, may also be influenced by genetic 
factors (e.g. Parathyras et al., 2009).  
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1.2 Nucleoside reverse transcriptase inhibitor (NRTIs) 
 
HIV-1 reverse transcriptase (RT) was discovered in the early stages as a potential target 
for antiretroviral treatment. HIV-1 RT is responsible for synthesis of a double-stranded 
proviral DNA from the viral RNA (Menendez-Arias, 2008). Nucleoside reverse 
transcriptase inhibitors (NRTIs) are analogues of the deoxyribonucleosides but lack the 
3’-hydroxyl group (OH) on their sugar moiety (Sluis-Cremer and Gilda Tachedjian, 2008). 
The NRTI analogues compete with the natural deoxynucleotide triphosphates (dNTPs) 
for incorporation into the newly synthesized strand, the inclusion and/or insertion of these 
nucleoside analogues results in viral DNA chain termination (de Béthune, 2010; Gallant, 
2002; Sluis-Cremer et al., 2004; Kakuda, 2000).  
There are eight NRTIs currently approved for clinical use, namely stavudine (d4T), 
lamivudine (3TC), didanosine (ddI), tenofovir (TDF), Abacavir (ABC), emtricitabine (FTC), 
Zidovudine (AZT), Zalcitabine (ddC) (Cihlar and Ray, 2010).  
The NRTIs in their administered form are inactive and require phosphorylation by cellular 
kinases to form active deoxynucleoside triphosphates (dNTP) analogues capable of viral 
inhibition (Kakuda, 2000; Figure 1.1). The antiviral activity of NRTIs is significantly 
influenced by intracellular phosphorylation kinetics (Stein and Moore, 2001). The 
sequential steps of NRTI phosphorylation from monophosphate to diphosphate to 
triphosphate can function as a rate-limiting step in the formation of an active drug (Stein 
and Moore, 2001). The intracellular concentration of NRTI-TP is regulated by a feedback 
mechanism of one or more enzymes in the phosphorylation pathway (Stein and Moore, 
2001). 
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Figure 1.1 The serial phosphorylation of NRTIs from their inactive administered form (prodrug) to their 
active triphosphate form (NRTI-TP), ABV, abacavir; d4T, stavudine; AMPD, adenosine monophosphate 
deaminase; AMPK, adenosine monophosphate kinase (Adenylate kinase); APT,adenosine 
phosphotransferase; dCMPK, deoxycytidine monophosphate kinase; ddA , 2’,3’-dideoxyadenosnie; ddl, 
didanosine; ddc, 2′-3′-dideoxycytidine; DP, diphosphate; CBV, carbovir; dCK, deoxycytidine kinase; ddC, 
Zalcitabine; FTC, emtricitabine; gK, guanylate kinase MP, monophosphate; PMPA , tenofovir (PMPA DP is 
a triphosphate analogue); TDF, tenofovir disoproxil fumarate; TP, triphosphate; ZDV, zidovudine; 
3TC,lamivudine; 5’NDPK, 5’nucleoside diphosphate kinase; 5’NT,5’nucleotidase (Anderson et al., 2004). 
 
 
 
 
 
 6 
 
1.3 Stavudine 
 
Zerit (Stavudine, d4T), 2’3’-didehydro-3’ deoxythymidine is a thymidine analogue that acts 
as a chain terminator like other NRTIs (Piliero, 2004). Stavudine is administered orally to 
HIV patients, and its oral bioavailability ranges from 82-99% for the dose range 0.1 to 12 
mg/kg (Lea and Faulds, 1996). Stavudine is reported to have an elimination half-life of 
1.5 hours for a standard dose of 40mg in HIV infected patients and a corresponding half-
life of 3.5 hours for the intracellular active metabolite stavudine-5'-triphosphate, in the 
peripheral blood mononuclear cells (Lea and Faulds,1996). Approximately 40% of 
stavudine in the plasma is renally excreted through the glomerular filtration and tubular 
secretion, with the remaining percentage thought to be eliminated through metabolism of 
pyrimidine salvage pathways and possibly degradation (Dudley et al., 1992; Hurst and 
Noble, 1999; Margolis et al., 2014).  
The peak plasma concentration (Cmax ) and area under the concentration-time curve 
(AUC) of stavudine occurred at a duration (Tmax ) 0.50 to 0.75 hours after oral dosing 
following a dose-dependent manner (Lea and Faulds, 1996). The peak plasma 
concentration of stavudine is affected by a high fat meal, which also delays the time to 
reach Cmax, but the overall bioavailability of stavudine is not affected (Riddler et al., 1995; 
Lea and Faulds, 1996).  Plasma clearance of stavudine is not dose-dependent nor body 
weight dependent (Riddler et al., 1995).  
1.4 Mitochondrial toxicity of NRTIs 
 
Regardless of the positive effects of the HAART, exposure to HAART can yield severe 
adverse events and morbidities (Walker et al., 2002; Calmy et al., 2007).  There are 
various complications associated with the use of ART in HIV positive patients. In 
particular, the NRTIs are associated with mitochondrial toxicity which results in a serious 
side effects such as hepatic steatosis (1% of the patients), peripheral neuropathy (7.5%), 
lipoatrophy (50%), lipomatosis (10%), and less frequently pancreatitis, cardiomyopathy, 
proximal myopathy, renal tubular acidosis (all<1%)(Carr, 2003).  
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Mitochondria are semi-independent organelles found in eukaryotic cells, which harbour 
their own genome and play a critical role in cellular energy production, formation of free 
radicals and apoptosis (Yu et al., 2013). The mitochondria harbour a diverse mtDNA 
genome that is 16 569 base pairs long and codes for 13 proteins as well as 2 ribosomal 
RNAs and 22 transfer RNAs that are signification for the translation of intra-mitochondrial 
proteins (Montier et al., 2009; Andreu et al., 2009). 
Mammalian cells can have over 100 mitochondria per cell with some having as much as 
1000 and furthermore each of these organelles has an mtDNA copy number ranging from 
two to ten, therefore a single human cell can have over 1000 mtDNA copies with some 
cells reaching 5000 mtDNA molecules (Moraes, 2001). Alterations in the nuclear genes 
involved in the synthesis of the mtDNA or responsible for the sustenance of 
deoxyribonucleotide molecules can greatly influence the mitochondrial copy number due 
to the inefficiency of mitochondrial biogenesis (Andreu et al., 2009). 
NRTI drugs are associated with mitochondrial toxicity due to their inhibitory activity of 
DNA polymerase gamma (POLG), an enzyme responsible for mtDNA replication (Walker 
et al., 2002; Figure 1.2). This results in the damage and loss of the mtDNA including 
decreased mtDNA copy number in many tissues (Cherry et al., 2002). This consequently 
weakens the ability of mtDNA to synthesize oxidative enzymes responsible for energy 
production in the oxidative phosphorylation pathway (Carr and Cooper, 2000).  There are 
significant differences in the relative potencies of NRTI in their ability to interact with 
POLG. The hierarchy of gamma-polymerase inhibition for the active NRTI metabolites 
has been determined as follows: zalcitabine (ddC,) > didanosine (ddI), > stavudine (d4T) 
> lamivudine (3TC) ≥ abacavir (ABC) ≥ tenofovir (TDF) ≥ emtricitabine (FTC) (Venhoff 
and Walker, 2011).   
The effects of stavudine on the mitochondria manifests in vivo as a reduction in the 
mtDNA copy number per cell in tissues such as the human adipose tissue and blood and 
as a result cause associated mitochondrial toxicities including pancreatitis, SN, 
lipodystrophy (Cherry et al., 2002).  
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The toxicities attributed to d4T are believed to be established through the inhibition of the 
human mtDNA polymerase gamma which plays a critical role in the replication and repair 
of the mtDNA, this inhibition subsequently results in the depletion of the mtDNA (Lewis, 
2003). NRTIs affect the functionality of the DNA polymerase gamma (POLG) which 
consequently perturbs the expression of vital mtDNA genes coding for proteins 
responsible for energy production and regulation of reactive oxygen species (ROS) 
(Kamerman et al., 2012).  
In addition, changes in mtDNA copy number due to POLG inhibition may not be the only 
mechanism underlying antiretroviral toxic neuropathy (ATN). ATN is a form of SN 
associated with the use of certain nucleoside antiretroviral drugs, see section 1.5 (Lewis, 
2003). Changes in the levels of dNTP pools can also be associated with ART-induced 
mitochondrial toxicity, independent of pol-γ inhibition (Selvaraj et al. 2014). Variation in 
the activity of d4T- specific drug transporters influences drug availability inside cells, d4T 
uptake by POLG, mtDNA copy number and resulting toxic side effects.    
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Figure 1.2 The proposed model by which NRTIs exert their toxicity to the mitochondria. The effects of the 
NRTIs (D4T) includes (1) the inhibition of the mtDNA polymerase  gamma which consequently leads to the 
depletion of the mtDNA as well as the degradation of the oxidative phosphorylation pathway which is 
manifested in three ways comprising (2) the perturbation of the respiratory complexes involved in the 
formation of the electron transport chain (3)  the disruption in the adenylate kinase (AK) function (4) and 
lastly the interference in the activity of the ADP/ATP translocator (T) (Keswani et al.,  2002). 
 
 
 
 10 
 
1.5 Sensory neuropathy 
 
Sensory neuropathy (SN) is a neurological disorder characteristic of HIV infection but the 
prevalence of SN has increased significantly by the initiation of antiretroviral therapy 
(Cherry et al., 2003). HIV-SN is subdivided into two categories, distal sensory 
polyneuropathy (DSP) due to HIV infection, and the antiretroviral toxic neuropathy (ATN) 
which stems from the use of NRTIs (Keswani et al., 2002; Kamerman et al., 2012). The 
only distinguishing factor of the aetiology of ART-induced SN from DSP is the time of 
onset after the exposure of NRTIs (McArthur et al., 2005). Hao (2013) reported that DSP 
and drug-induced SN portray the same clinical manifestations. The symptomatic features 
of SN are predominantly characterised by pain, loss of sensation (McArthur et al., 2005), 
numbness, pins and needles and signs that can be measured including loss of ankle 
reflexes and loss of vibration sense (Wadley et al., 2011).  
Both DSP and ATN affect the peripheral nerves (Pardo et al., 2001) and are characterised 
by the erosion of the size-dependent nerve fibres (Kamerman et al., 2012). The most 
common neurological descriptive feature of HIV-SN is the loss of dorsal root ganglions as 
well as the degeneration of long axons on the distal regions (Pardo et al., 2001), this 
phenomenon is often referred to as the ‘dying back’ pattern of axonal degeneration 
(Keswani et al., 2002). 
The primary step after excluding metabolic causes in treating HIV-SN is the consideration 
for withdrawal and dose reduction of neurotoxic antiretroviral drugs such as didanosine, 
stavudine, zalcitabine (Wulff et al., 2000).  
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1.6 Pharmacogenetics of SN 
 
Not all patients who are exposed to NRTIs develop mitochondrial toxicity such as sensory 
neuropathy. This suggests that factors such as underlying genetic variation can influence 
the development of SN in response to NRTI use. Pharmacogenetics refers to the study 
of altered drug response as a result of the genetic changes in the genes affecting the 
pharmacokinetics (drug transporters, drug metabolizers) and pharmacodynamics (drug 
targets) of drugs (Kalow, 2002;Johnson, 2003) and this may help to predict who suffers 
off-target side-effects of ART and who does not. 
In particular, human genetic variation could influence SN development in a variety of 
ways: 
 
1. Variation in the genes affecting drug transport into and out of cells could influence the 
relative amounts and concentrations of drug in plasma and inside cells of the tissues.    
2. Variation in the genes affecting drug metabolism e.g. phosphorylation, activation, 
breakdown and excretion of the drug, further influencing relative amounts and 
concentrations of active drug in plasma and inside cells of the tissues.   
3. Variation in genes affecting immune responses to HIV, including cytokines and the 
MHC region.  
4. Variation in genes affecting pain neurology or pain perception.  
5. Variation in genes controlling mtDNA copy number or function, since POLG inhibition 
is thought to be the mechanism by which NRTI toxicity arises.  
 
Genes in (3) and (4) have been the focus of series of studies in the same cohort studied 
here, conducted by our collaborators in the School of Physiology, Faculty of Health 
Science, University of the Witwatersrand. Genes that have already been examined in the 
cohort under current investigation, include TNFa haplotypes, several cytokines, 
Uncoupling protein (UCP), GTP cyclohydrolase 1 (GCH1), Potassium voltage-gated 
channel subfamily 1 (KCNS1), Interleukin 1b (IL1B), Interleukin 6 (IL6), Monocyte 
chemoattractant protein-1 (CCL2) and CC motif chemokine receptor–2 (CCR2) (Hendry, 
2014; Wadley et al., 2011; Wadley et al., 2013a; Wadley et al., 2013b; Wadley et al., 
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2014). Genes in (5) are the subject of another current study in the School of Molecular 
and Cell Biology. 
 
Collectively the pharmacogenes in (1) and (2) are sometimes referred to as the 
absorption, distribution, metabolism, and excretion (ADME) genes since they determine 
drug absorption, distribution, metabolism and excretion / elimination (Kerb et al., 2009). 
These can be core determinant of the toxicities and efficacies of ARVs (Michaud et al. 
2012; Johnson, 2003).  In addition, many of the same ADME genes also control the 
relative levels of the natural dNTP pool with which the NRTIs compete inside the cells.  
Variation in endogenous dNTP or RN levels could be a key second mechanism by which 
NRTI toxicity occurs (Selvaraj et al., 2014).  Decreased endogenous dNTP pools result 
in higher incorporation of the NRTI triphosphate (Rampazzo et al. 2010) and could cause 
both increased NRTI efficacy and increased NRTI toxicity. For example, Selvaraj et al. 
(2014) found that HIV infected individuals on ART who had mitochondrial toxicity had 
lower ribonucleotide (RN) and deoxyribonucleotide (dRN) pools compared to infected 
individuals on ART who did not have mitochondrial toxicity.  
 
Genetic variations in the ADME genes and their influence on the development of SN and 
on CD4 count recovery are the focus of the current study.  The following sections 
therefore review: Thymidine/dTMP synthesis and metabolism pathways (in section 1.7) 
as well as dTTP and d4T drug transporters (in section 1.8).  
1.7 dNTP synthesis and metabolism pathways 
 
The cell requires the four dNTPs (adenosine, thymidine, cytosine, and guanine) in 
adequate supply in order to replicate and repair its DNA efficiently, for sufficient 
mitochondrial function and in order for cell division to occur (Reichard, 1988). The 
availability of dNTP in cells is governed by two primary pathways, namely, the de novo 
pathway and the salvage pathway (Rompay et al., 2000). 
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1.7.1 de novo synthesis of pyrimidines  
 
The liver is the major organ of de novo synthesis of all four nucleotides.  The de novo 
dNTP pathway involves creation of new dNTP precursors (deoxyribonucleotides) from 
carbohydrate and amino acid metabolism (Christiansen et al., 2015). De novo synthesis 
is cell cycle-regulated, operative during the S-phase of DNA replication in cells 
(Christiansen et al., 2015).  
The de novo synthesis of all pyrimidines occurs by the following steps:  
 Glutamine and bicarbonate are combined to make carbamoyl-phosphate.  
 Carbamoyl-phosphate is then used to make the common precursor ring structure 
orotic acid (orotate) (O'Donovan & Neuhard, 1970).  
 A phosphorylated ribosyl unit (phosphoribosylpyrophosphate or PRPP) is added 
to orotic acid, to create a pyrimidine nucleotide called orotidylate (OMP) 
(O'Donovan & Neuhard, 1970).   
 Decarboxylation of OMP yields uridine monophosphate (uridylate or UMP). 
 It is from UMP that other pyrimidine nucleotides are derived, including both 
ribonucleotides and deoxyribonucleotides (Löffler et al., 2005). 
All the steps summarised above are illustrated in the figure below (Figure 1.3). 
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Figure 1.3 de novo synthesis of pyrimidines (modified from www.themedicalbiochemistrypage.org, 2015).  
This process is explained further below. 
 
This de novo pathway is used for synthesis of both the ribonucleotides and the 
deoxyribonucleotides.  
However due to relatively large pools of ribonucleotides compared to 
deoxyribonucleotides, the major pathway of deoxyribonucleotide synthesis is from 
existing ribonucleotides being converted to deoxyribonucleotide (e.g. UMP to dTMP) by 
the enzyme ribonucleotide reductase (RNR).  
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The RNR is the only enzyme capable of converting ribonucleotide to 
deoxyribonucleotides and therefore is a rate-limiting step for the production of 2-
deoxyribonucleoside 5-triphosphates (dNTPs) that are necessary for DNA replication 
(Heidel et al., 2007). Ribonucleotide reductase (RNR) is a multimeric enzyme that 
consists of two subunits: the large subunit (RRM1 or R1) and the small subunit (RRM2 or 
R2) (Jørgensen et al., 2013). 
The R1 protein is present throughout the cell cycle while the R2 subunit is only expressed 
during the late G and early S phase during DNA replication (Heidel, 2007).   
For purposes of this study the synthesis of dTTP, the competitor of d4T, is described, and 
shown in Fig 1.4.  UMP is phosphorylated to UDP by uridylate kinase and UDP is then 
converted to dUDP by the enzyme ribonucleotide reductase (RNR) (Hauschka, 1973).  
dUDP does not get converted directly to dUMP. dUDP is phosphorylated again to dUTP 
by nucleoside diphosphate kinase, which is then broken down to dUMP by dUTPase.   
Finally, dUMP is converted to thymidine monophosphate (dTMP or thymidylate) by the 
enzyme thymidylate synthase. dTMP can then be further phosphorylated by the enzymes 
thymidylate kinase and nucleoside diphosphate kinase to dTTP, the active form of 
thymidine used in DNA synthesis (Christiansen et al., 2015).     
Isoforms of some of the enzymes in the de novo pathway are found only in the 
mitochondria and allow ongoing dNTP synthesis in non-dividing cells (Christiansen et al., 
2015), including: 
 P53R2 or RRM2B isoform of RNR  
 mitochondrial isozyme of DHFR called DHFRL1 
 mitochondrial form of dUTPase  
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Figure 1.4 Thymidylate synthesis pathways (collated by D de Assis Rosa). Substances in boxes/purple 
texts are part of the de novo synthesis pathway, while all other substances are part of the salvage pathway. 
OMP, Orotidine 5’-phosphate; UMP, Uridine 5'-monophosphate; UDP, Uridine 5'-diphosphate; UTP, 
Uridine-5'-triphosphate, dC, 2’-deoxycytidine; dU, 2'-deoxyuridine; dCMP, 2'-Deoxycytidine 5'-
monophosphate; dUMP; 2'-deoxyuridine-5'-monophosphate;dUDP, 2'-Deoxyuridine 5'-diphosphate;dUTP, 
2'-Deoxyuridine 5'-triphosphate;dTTP, 2'-deoxythymidine-5'-triphosphate;dTDP, thymidine 5'-diphosphate 
;dTMP, Thymidine Monophosphate ; ATP, Adenosine triphosphate ;SAMDH, The sterile alpha motif and 
HD-domain containing protein 1. 
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1.7.2 Folate cycle 
 
The production of dTMP by thymidylate synthase (TS) is tightly linked to the folate / 
methionine cycle (Figure 1.5.). Folates are naturally occurring water-soluble members of 
the Vitamin-B class essential for maintaining the synthesis of thymidine and purines, 
actively involved in the amino acids conversions and also required for the methylation of 
essential biological substances such as DNA, proteins, phospholipids and 
neurotransmitters (Chango et al., 2000; Hamid et al., 2009; Crider et al., 2012).  
Dihydrofolate reductase (DHFR) enters the system from dietary folic acid (vitamin B9). 
The reduced folate carrier RFC encodes a transmembrane anionic exchanger which 
serves as carrier of folate into the cells. The enzyme DHFR converts the DHF to 
tetrahydrofolate (THF) (Main et al., 2010). THF becomes a recipient of a methyl group 
during the conversion of serine to glycine catalysed by enzyme SHMT, and THF is 
converted to (5, 10-MTHF) (de Silva & Davis, 2013). During de novo dTMP synthesis, 
enzyme thymidylate synthase (TS) uses a methyl group donated by 5, 10 methylene 
tetrahydrofolate (5, 10-MTHF) as a cofactor to maintain the dTMP pool necessary for 
DNA repair and synthesis (Trinh et al., 2002) (Figure 1.5).  
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Figure 1.5 Folate and the thymidylate cycle mediated dTMP synthesis. Red box indicates 
occurrence of dTMP production within this cycle. AICAR= aminomidazole carboxamide ribonucleotide; 
AICART = AICAR formyl transferase; B=vitamin B (cobal-amin);CYH = methenyl-THF-cyclohydrolase; 
DHF= dihydrofolate; DHFR=DHF reductase; dTMP = deoxythymidine monophosphate; dUMP= 
Deoxyuridine monophosphate; FAICAR = formyl-AICAR;FGAR =formyl-GAR; GAR = glycinamide 
ribonucleotide; GART=GAR formyl transferase; MS=Methionine synthase; MTHFD = methylene-THF-
dehydrogenase; MTHFR=5,10-methylene-THF-reductase;NADP = nicotinamide adenine dinucleotide 
phosphate; NADPH = reduced NADP; SHMT = serine hydroxyl methyltransferase ; THF=tetrahydrofolate; 
TS = thymidylate synthase (Pietrzik et al., 2010). 
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1.7.3 Salvage pathway of dNTP production  
 
The salvage pathway is a complementary process for dNTP synthesis (Figure 1.3). The 
activation of a number of antiviral prodrugs (including d4T) is also performed using the 
salvage pathway (Sandrini & Piskur, 2005). The phosphorylation of deoxyribonucleosides 
to their monophosphate metabolites is catalysed by deoxyribonucleoside kinases (Knecht 
et al., 2002). The two deoxyribonucleoside kinases relevant to thymidine salvage and d4T 
activation in humans are thymidine kinase 1 (TK1, active in cytosol) and thymidine kinase 
2 (TK2, active in mitochondria). There are also two deoxyribonucleoside kinases not 
relevant to thymidine salvage or d4T activation:  deoxycytidine kinase (dCK) and 
deoxyguanosine kinase (dGK), due to the fact that these two kinases do not play a role 
in the phosphorylation of d4T to  the active metabolite d4T-TP, which begins with the rate-
limiting step of TK1 or TK2 to d4T-MP. 
Lastly, dTTP may be converted back to unphosphorylated thymine (dT) by the enzyme 
SAMHD1; however, this enzyme does not hydrolyse active d4T back to its 
unphosphorylated form (Ballana et al. 2014).   SAMHD1 activity may increase efficacy of 
thymidine analogs by reducing competition with intracellular dNTP (Amie et al., 2013). 
dNTP synthesis by the salvage pathway, particularly in the presence of mitochondrial 
damage, may be boosted by the activity of PINK1, a protein more traditionally thought to 
be involved in Parkinson’s disease (Tufi et al. 2014). 
In summary, the following Table 1.2 shows the key enzymes which influence de novo 
and salvage thymidine synthesis and therefore control endogenous levels of dTMP and 
its derivatives such as dTTP.  Many of these enzymes play a role in the phosphorylation, 
activation and metabolism of both endogenous thymidine and d4T.   
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Table 1.2 Enzymes which control thymidine and d4T metabolism.  
Enzyme Abbreviation Gene Chromosomal 
position of gene 
Ribonucleotide reductase subunit 1 RNR1 RRM1 11p15.5 
Ribonucleotide reductase subunit 2 RNR2 RRM2 2p25-p24 
Ribonucleotide Reductase 
Regulatory TP53 Inducible Subunit 
M2B 
p53R2 RRM2b 8q22.3 
Nucleoside Diphosphate Kinase NDPK-A NME1 17q21.3 
deoxyuridine triphosphatase dUTPase DUT 15q21.1 
Thymidylate synthetase TS TYMS 18p11.32 
Dihydrofolate reductase DHFR DHFR 5q11.2-13.2 
Dihydrofolate reductase-like 1 DHFRL1 DHFRL1 3q11.1 
 
Methylenetetrahydrofolate MTHF MTHFD1 14q24 
Thymidine kinase   TK1 TK1 17q23.2-q25.3 
 
Mitochondrial thymidine kinase 2  TK2 TK2 16q21 
Thymidylate Kinase dTMP kinase  DTYMK 2q37.3 
SAM domain and HD domain 1 SAMHD1 SAMHD1 20pter-q12 
 
PTEN induced putative kinase 1 PINK1 PINK1 
PARK6 
1p36 
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1.8 Transporter proteins 
 
Membrane transporter proteins are responsible for the influx and efflux of critical 
compounds across biological membranes (Hediger et al., 2004; Goole et al., 2010). The 
transporters expressed in tissues like the intestine, liver, brain and kidneys play a very 
crucial role in the absorption, distribution and excretion of many drugs used daily in clinical 
practise (Telenti and Zanger, 2008). There are two types of drug transporters:  uptake 
and efflux transporter proteins. The uptake transporters facilitate the influx of biological 
compounds across the lipid bilayer in the cytosol, whereas efflux transporters mediate the 
efflux of compounds out of the cells (Hediger et al., 2004; Goole et al., 2010).  
 
Transporter proteins are clustered into two major families of transporters, namely the 
solute carriers (SLC) and the ATP-binding cassette (ABC) superfamilies (Estudante et 
al., 2013) which are generally uptake and efflux transporter proteins respectively (Konig 
et al., 2013). The SLC proteins facilitate movement of substances across the membranes 
into cells through the use of the electro-chemical gradient of solutes, whereas the ABC 
proteins utilize the energy derived from the hydrolysis of ATP in order to move substrates 
across the membranes out of cells as well as to circumvent the concentration gradients 
of the solutes (Cascorbi, 2006; De Gorter et al., 2012).  
 
The SLC superfamily of transporter proteins comprises of more than 300 proteins which 
are classified into subfamilies. The subfamilies are assigned numbers from 1 to 52 after 
the root name SLC and the corresponding genes are identified by the family name 
followed by the letter A and the corresponding numeral assigned to that particular gene 
(Hedigar et al., 2013), e.g. SLC22A6. The ABC transporter genes are divided into seven 
families denoted the letters A-G (Vasiliou et al., 2009), followed by a number representing 
the gene e.g. ABCB1.  
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1.8.1 Transport of nucleotides /nucleoside  
 
Nucleotides/nucleosides and nucleoside-derived drugs are hydrophilic molecules and 
diffuse, if they can, slowly across cell membranes;  more often specific membrane 
transporters that mediate their flux across cell membranes are required (Pastor-Anglada 
& Perez-Torras, 2015). The genes encoding transporter proteins are highly polymorphic 
which therefore yields varied expression levels and enzyme-substrate specificities and 
thus compromises the optimal function of these proteins as well as drug efficiency 
(Sissung et al., 2010). 
 
Transporter proteins have been studied lengthily in vitro using c-RNA injected Xenopus 
laevis oocytes and transfected mammalian cell lines and in vivo using animal models 
such as the knockout mice and many others (DeGorter et al., 2012).Transport proteins 
mediate the transmembrane transport of critical drugs and substances such as amino 
acids and nutrients  by mediating their metabolism, absorption, distribution and 
elimination.Transport proteins controlling nucleotide entry into cells are encoded by three 
gene families: SLC22, SLC28, and SLC29 (Pastor-Anglada et al., 2005). Nucleotide efflux 
is controlled by transport proteins from the ABCB, ABCC and ABCG families (Chan, 
Lowes and Hirst, 2004).  
 
1.8.1.1 SLC22 gene family 
 
The SLC22 gene family encodes organic anion transporters (e.g., OAT1 and OAT2) and 
organic cation transporters (e.g., OCT1 and OCT2), implicated in the uptake of 
nucleoside-derived drugs (Minuesa et al., 2011). Burckhardt (2012) reported that the rat 
oat1 transports nucleoside prodrugs such as stavudine   and zidovudine and Pastor-
Anglada et al. (2005) identified the OAT1 protein (SLC22A1) as a transporter of the d4T 
nucleoside analogue.   
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1.8.1.2 SLC28 family 
 
The SLC28 family encodes concentrative nucleotide transporters. The human 
concentrative nucleoside transporter protein family has three members, hCNT1, 2, and 
3, encoded by SLC28A1, A2, and A3 genes, respectively. hCNT1 and hCNT2 translocate 
pyrimidine- and purines -, by a sodium-dependent mechanism.  There is some debate 
whether the CNT family transport ARVs (e.g. Mangravite et al., 2003), and Minuesa et 
al., 2011 vs. Pastor-Anglada and Perez-Torras 2015 and Cano-Soldado et al., 2004).” 
hCNT1 has the capacity to transport azidothymidine and stavudine although with a low 
capacity (Minuesa et al., 2011).  For those nucleoside analogues which are trans-located 
by CNT1, this occurs at a very low affinity (Cano-Soldado & Pastor-Anglada, 2012). The 
human CNT3 shows broad substrate selectivity and the unique ability of translocating 
nucleosides both in sodium- and a proton-coupled manner, and d4T is an hCNT3 
substrate (Molina-Arcas et al., 2009). 
 
1.8.1.3 SLC29 gene family 
 
The SLC29 gene family encodes for four equilibrative nucleotide transporters (e.g., ENT1, 
ENT2, ENT3 and ENT4) which are involved in the mediation of facilitated diffusion and 
sodium independent transport (Molina-Arcas et al., 2009). The ENTs 1 and 2 are w widely 
expressed across human tissues (Molina-Arcas et al., 2009). The ENT3 as well ENT1 
and ENT2 nucleoside transporter proteins serve as transporters of both the pyrimidines 
and purines with significantly varying substrate specificities (Cano-Soldado & Pastor-
Anglada, 2012). ENT3 was identified as an uptake transporter of d4T (Cano-Soldado & 
Pastor-Anglada, 2012; Pastor-Anglada & Perez-Torras, 2015). The level of expression of 
the ENT3 transporter on the mitochondria is associated with the corresponding 
transportability of nucleoside analogue prodrugs (Minuesa et al., 2011). 
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1.8.1.4 ABCB family 
 
The most studied ABC drug transporter is the p-glycoprotein (P-gp) also known as the 
multidrug resistance protein 1 (MDR1) efflux transporter encoded by the MDR1 (ABCB1) 
gene (Michaud et al., 2012). Kis et al. (2010) identified d4T as an inhibitor of the p-
glycoprotein transporter protein.   
.  
1.8.1.5 ABCC family: MRP5 
 
The multi-drug resistant protein 5 (MRP5) encoded by ABCC5 gene has been evidenced 
to transport d4T-MP (Marc¸al Pastor-Anglada et al., 2005). The MRP4 and 5 belong to 
the sub-family C of the ABC superfamily and both possess the 12 trans-membrane α-
helices and are devoid of the additional membrane spanning domain at the N-terminus 
(Gradhand and Kim, 2008). The extent of information on the genetic variants and 
endogenous function of the ABCC5 is less (Gradhand and Kim, 2008).    
 
Fukuda and Schuetz (2012) reported that ABCC-family genes are critical in the 
determination of intracellular of nucleotide metabolites. Schuetz et al. (1999) first 
demonstrated interaction of reverse transcriptase inhibitors with MRP4 such as the 
monophosphorylated form of zidovudine, confirming the ability of MRP4 to interact with 
phosphorylated nucleosides. d4T is an MRP5 substrate, therefore it is transported out of 
the cell through the MRP5 efflux protein (Schuetz et al., 1999; Reid et al., 2003). The 
MRP5 transporter protein is expressed in the colon, liver, kidney, and skeletal muscles 
and consequently facilitates the efflux of d4T (Choudhuri, 2006).  
 
1.8.1.6 ABCG family: BCRP 
 
The (ABCG2, MXR, ABCP, BCRP) gene encodes for a breast cancer resistant protein 
(BCRP) a transporter protein that serves as an efflux transporter and shares the same 
tissue distribution with the ABCB1 gene transporter protein (Michaud et al., 2012).  
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Fukuda and Schuetz (2012) reported that ABCG2 genes are critical in the determination 
of intracellular nucleotide metabolites. The BCRP transporter is abundantly expressed in 
the liver, small intestines and lymphocytes. Cells transfected with the BCRP transporter 
protein showed reduced accumulation of d4T (Kis et al., 2010). 
 
Similar transporters are used to transport nucleoside-derived drugs such as ARVs. Drug 
transporters can influence antiretroviral therapy outcomes in many ways: 1) bioavailability 
(intestinal and hepatic transporters); 2) antiretroviral penetration in sanctuary sites (e.g., 
brain, vaginal mucus, testicles); and 3) access in target cells (lymphocytes) (Michaud et 
al., 2012). Table 1.3 shows the transporters responsible for d4T influx or efflux and which 
help control plasma and intracellular concentrations of d4T, as well as influencing relative 
levels of endogenous dN/dNTP and RN pools.  
 
Table 1.3 The d4T nucleoside analogue drug transporters. 
Transporter 
Protein 
Influx or 
efflux 
Reference for 
role of this 
protein in d4T 
transport 
Abbreviation Gene Location 
Breast cancer resistant 
protein 
efflux Kis et al.,2010 BCRP ABCG2 4q22 
Multi-drug resistant 
protein  5   
efflux Kis et al., 2010 MRP5 ABCC5 3q27.1 
Concentrative nucleoside 
transporter  1  
influx Kis et al., 2010 CNT1 SLC28A1 15q25.3 
Concentrative nucleoside 
transporter  3  
influx Minuesa et 
al.,2011 
CNT3 SLC28A3 9q21.32-
q21.33 
Equilibrative nucleoside 
transporter 3  
influx Minuesa et al., 
2011 
ENT3 SLC29A3 10q22.1 
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1.8.2 ADME genes associated with sensory neuropathy  
 
A number of genes involved in antiretroviral drug metabolism and transport have been 
implicated in the variable drug outcomes which lead to disparities in drug efficacy and the 
emergence of adverse drug reactions (Domingo et al., 2011; Domingo et al., 2013a). 
Domingo et al. (2013a) reported the association of polymorphisms in the MTHFR and TS 
genes with mitochondrial toxicity further mentioning that the genotypes that have a 
negative impact on the TS activity have been found to be associated with higher d4T-TP 
intracellular levels and fat redistribution. In 2011 Domingo et al. reported that TS 
genotypes associated with lessened activity of the enzyme would increase the 
competitive advantage of d4T-TTP against the natural dTTP pool (Domingo et al., 2011).  
 
The TS enzyme play a key role in the denovo synthesis of pyrimidines, and the variable 
number tandem repeat (VNTR) polymorphism of the TS gene located on its promoter 
region has been shown to influence the d4T-TP intracellular levels (Domingo et al., 
2013b). Domingo et al. (2011), reported that mutations that are associated with 
diminished expression of the enzyme TS are associated with increased levels of d4T-TP 
due to the increased competitive advantage of d4T-TP which follows upon reduced dTTP 
levels.  
 
The pathogenesis of mtDNA toxicity by NRTIs involves the regulation of natural dNTP 
pool sizes in the mitochondria which affects mitochondrial DNA replication (Domingo et 
al., 2011). The elevated d4T-TP intracellular levels saturate the mitochondrial dNTP pool 
space and start inhibiting the mitochondrial polymerase gamma (POLG) the enzyme 
responsible for mtDNA replication, consequently mtDNA toxicity arises and the adverse 
drug reactions associated with it such as SN, lipodystrophy and are experienced. 
 
Sterile alpha motif and histidine-aspartic domain-containingprotein 1 (SAMHD1) is a 
recently discovered HIV-1 host restriction factor that prevents retroviral replication at the 
reverse transcription stage (Ballana et al., 2014). Pauls et al. (2014) reported that dNTPs 
used for DNA replication are controlled by various enzymes and one of the enzymes that 
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tightly controls the dNTPs is the dNTP triphosphohydrolase SAM domain and HD domain-
containing protein 1 (SAMHD1). SAMHD1 dephosphorylates dNTPs reducing them to 
concentrations below the threshold level required for RNA or DNA replication (Ballana et 
al., 2014).   
 
NRTIs such as d4T compete with natural dNTPs for newly transcribed DNA at the RT 
step, for this reason it is hypothesized that SAMHD1 may influence HIV-1 sensitivity to 
NRTIs (Ballana et al., 2014). SAMHD1 targets naturally occurring dNTPs and not 
synthetic dNTPs such as d4T as a result this gives NRTI drugs such as d4T-TP a 
competitive advantage over natural dNTPs (Lewis et al., 2003). Elevated levels of 
intracellular d4T-TP lead to mtDNA toxicity and associated adverse events such SN. 
 
Alterations in the metabolism of iron leads to mitochondrial dysfunction because iron 
plays a critical role in metabolically active cells such as neurons which require a consistent 
supply of iron in order to maintain events such as mitochondrial function, axonal activity 
and myelination (Vidal et al., 2010; Kallianpur et al., 2014).  Macrophage-mediated 
inflammation is regulated in part by iron transport through the hepcidin pathway 
(Kallianpur et al., 2014).  
 
Vidal et al. (2010) reported that heterozygous carriers of the HFE C282Y genotype that 
were receiving treatment with ddl and d4T encountered a reduced impact of sensory 
neuropathy in all racial groups. The HFE H63D polymorphism also reported a reduced 
occurrence of the incidence of sensory neuropathy in the univariate analysis but lost 
significance after adjustment for multiple testing (Kallianpur et al., 2014).  
1.8.3 ADME genes associated with CD4+ T cell recovery after ART 
 
Several genetic variants in metabolism genes of the ADME pathways have been 
associated with drug plasma levels and CD4+ T cell recovery after ART (Parathyras et 
al., 2009; Yimer et al., 2012).  
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Variations observed in CYP2B6, which encodes the predominant enzyme for the 
elimination of efavirenz and nevirapine ART drugs has an effect on the variable systemic 
exposure, plasma levels and efficacy of the treatment (Sarfo et al., 2013). However d4T 
is not transported by CYP2B6. 
 
Rotger et al. (2006) reported that the genetic marker CYP2B6 516T only found within the 
black population was associated with high EFV levels. Elens et al. (2010) also found that 
the CYP2B6 516T polymorphism was associated with EFV plasma levels. Queiroz et al. 
(2017) reported that patients carrying the CYP2B6 516T TT genotype who use EFV, may 
present adverse effects such as liver or kidney toxicity that interferes with their reaction 
to the treatment and therefore leading to a lower CD4+ T cell count. However the patients 
in the current study were not using efavirenz and CYP2B6 does not metabolise d4T.  
 
The CYP2B6 516T polymorphism is a missense variant that results in an amino acid 
change from glutamine to histidine at position 172 of the protein is associated with 
decreased expression and function of CYP2B6. Nevirapine (NVP) which is one of the 
highly used NNRTI drugs induces CYP3A4 and CYP2B6 (Arab-Alameddine et al., 2011). 
Saitoh et al. (2007) demonstrated that the CYP2B6-G516T polymorphism is associated 
with the pharmacokinetic of NVP and CD4 cell count response in children carrying the 
CYP2B6 516TT genotype. 
 
The MDR1/ABCB1 gene encoding for the multidrug efflux pump P-glycoprotein (P-gp) 
has been reported to limit the entry of protease inhibitors into CD4+ T cells (Haas, 2005). 
Several mutations and SNPs for the ABCB1 gene such as 3435C>T (rs1045642) have 
been reported some of which affect the expression and function of the P-glycoprotein 
(Haufroid, 2011).  
 
Black (Xhosa) and Coloured HIV patients of South Africa (SA) homozygous for the C 
allele of SNP T-129C of the ABCB1 gene reported to have encountered elevated levels 
of CD4 cell count compared to patients heterozygous for the same SNP who also 
exhibited intermediate levels of immune recovery between that of patients having the CC 
 29 
 
and TT genotypes (Parathyras et al., 2009).   The ABCB1 (3435C>T, exon 26) 
polymorphism has been associated with altered P-glycoprotein expression and is also 
reported to increase CD4+ T cells recovery as a result of elevated plasma concentration 
levels of efavirenz and nelfinavir (Haas, 2005).       
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1.9 AIM AND OBJECTIVES 
1.9.1 Aim 
To investigate the association of single nucleotide polymorphisms in d4T drug transporter 
genes and dNTP pool regulator genes and their association with response to d4T-ART. 
 
The aim of the study was broken down and explained into several more specific 
hypotheses and aims as follows: 
1. To investigate the association of selected single nucleotide polymorphisms in d4T drug 
transporter genes and dTTP pool regulator genes with the development of sensory 
neuropathy (SN) in individuals exposed to d4T, using a case-control cohort.  
This work was done to investigate the hypothesis that ADME genetic variants could 
change the amounts of active drug available inside cells and therefore influence ART-
mediated toxicity. SN is one type of ART-mediated toxicity.  
 
2. To investigate the association of selected single nucleotide polymorphisms in d4T drug 
transporter genes and dTTP pool regulator genes with mtDNA copy number in blood from 
individuals exposed to d4T.   
This work was done to investigate the hypothesis that ADME genetic variants could 
change the amounts of active drug available inside cells and therefore influence the 
amount of ART-mediated mitochondrial damage that occurs.   MtDNA copy number was 
used as another indicator of ART-mediated toxicity.  
 
3. To investigate the association of SNPs of d4T transport genes with cross-sectional post 
treatment CD4+ T cell counts in individuals exposed to d4T. 
This work was done to investigate the hypothesis that ADME genetic variants could 
change the amounts of active drug available inside cells and therefore influence the CD4+ 
T cell response to ARV treatment.   Only cross-sectional CD4+ T cell counts from a single 
time point post-ART were available for this analysis. 
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1.9.2 Objectives 
 
1. To choose ~30 relevant SNPs in ADME genes to be examined in the current study.   
2. To genotype chosen candidate SNPs using Sequenom assays, in samples from a 
case-control cohort, with and without SN after d4T use.  
3. To examine statistical associations between candidate SNPs and development of 
sensory neuropathy. 
4. To use a qPCR assay to compare mtDNA copy number in individuals with sensory 
neuropathy and without sensory neuropathy after d4T use. 
5. To examine statistical associations between candidate SNPs and mtDNA copy 
number. 
6. To examine statistical associations between ADME SNPs and single cross-sectional 
post treatment CD4 counts in this cohort. 
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CHAPTER 2: METHODS AND MATERIALS 
2.1 Cohort 
2.1.1 Patient recruitment 
 
Unrelated patients of Black African descent from the Southern African Developmental 
Countries (SADC) were recruited at the Virology Clinic of the Charlotte Maxeke 
Johannesburg Academic Hospital, South Africa in 2008-2009, using the following 
eligibility criteria: all participants were 18 years or above, all participants were HIV positive 
with a confirmed diagnosis, all participants were on an antiretroviral therapy programme 
containing stavudine for at least six months. Blood samples were collected and DNA 
extraction done by Mrs A. Wadley as part of her PhD study (School of Physiology, Brain 
Function Research Group, University of the Witwatersrand), and the study was approved 
by the Human Research Ethics Committee (Medical), University of the Witwatersrand, 
(protocol no. M080220). Informed consent was obtained from all participants in a written 
format, an interpreter fluent in commonly spoken native languages and in English 
facilitated consent and study protocol. The study conformed to the declarations of Helsinki 
2008. The number of patients initially assessed for eligibility and participation in the study 
were 482. A total of 404 participants were finally recruited and DNA samples from 342 
patients were analysed by Wadley et al. in their studies (Wadley et al., 2011; Wadley et 
al., 2012; Hendry et al., 2013). 
2.1.2 DNA Extraction and quantification 
 
The initial 19 DNA samples were extracted from saliva; this was carried out using the 
QIAamp DNA Mini-kit (QIAGEN; Valencia, CA). The QIAamp DNA Mini-kit is a silica-
membrane based DNA purification protocol that comprises of four steps carried out using 
QIAamp spin-columns in a micro-centrifuge tube. The rest of the DNA samples were 
extracted from the blood cells using the salting out method (Miller et al. 1988). This is a 
procedure that lyses cells using either SDS or proteinase K, followed by the salting out of 
proteins using sodium chloride (NaCl) from the solution and lastly the precipitation of DNA 
using ethanol. The DNA was later stored at -20°C. 
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Of the original 342 DNA samples extracted by Dr Wadley, many of the samples were sent 
to other collaborators or had degraded DNA. A total of 263 DNA samples that remained 
were used in the current study. The current study attained ethical clearance from Human 
Research Ethics Committee (Medical), University of the Witwatersrand, (protocol no. 
M150459, Appendix A). 
The DNA quantity was determined from the concentration of the DNA sample, by 
measuring its absorbance at a wavelength of 260 nm using the spectrophotometer 
instrument (NanoDrop® ND-1000). Double distilled water was used to dilute the samples 
to a working concentration of 25 ng/µl. Purity was determined by calculating the ratio at 
absorbance 260 nm and absorbance 280 nm known as the A260/280 ratio. An 
absorbance ratio of 1.8-2.0 is generally accepted as pure for DNA. 
2.1.3 Phenotype 
 
Peripheral sensory data was gathered from the participants by Dr Wadley at the time of 
sampling using the brief peripheral neuropathy screening tool from the AIDS Clinical 
Trials Group (ACTG) (Chery et al., 2005).  
The participants were deemed to have symptomatic HIV-SN if they experienced at least 
one symptom (pain, aching, burning, numbness, or pins and needles) and at least one 
clinical sign of neuropathy (reduced vibration sense or absent of ankle reflexes) in each 
leg (Wadley et al., 2011). Of the 263 participants used in the current study, 54% (n=143) 
were diagnosed to have symptomatic HIV-SN and therefore were assigned as cases and 
46% (n = 120) reported no symptoms of HIV-SN and therefore were assigned as controls 
(Figure 2.1). 
Demographic and clinical data of the patients such as age, sex, ethnicity and clinical 
information including duration of HIV infection, AIDS-defining illnesses, antiretroviral 
treatment record and other potential causes of neuropathy such as diabetes mellitus, 
alcoholism, vitamin B12 deficiency, exposure to isoniazid and chemotherapy were 
obtained. The participants’ weight and height were recorded and their venous blood 
samples taken for hepatitis C serology.  
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Nadir (lowest ever) CD4+ T cell counts and CD4 + T cell counts at the time of phenotyping 
were recorded.  Participants had spent variable lengths of time on ART (at least 6 months) 
and the CD4+ T cell count data were therefore cross-sectional, and not all from the same 
time point post- ART initiation.  
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Figure 2.1 Patient inclusion and exclusion diagram, modified from Wadley et al. (2014). 
HIV-positive adults attending 
Virology Clinic 
Assessed for eligibility 
n = 482 
Excluded (total n= 78) 
Incomplete assessment                           n= 10 
Patient entered study twice                     n = 3 
On ARVs <6 months                               n = 37 
Missing medical files                               n = 28 
Total samples 
recruited 
n= 404 
 
Excluded (total n=141) 
Black of non-Southern African origin     n= 6 
Other causes of SN                                 n= 14   
Futile DNA extraction                              n= 14 
Degraded DNA                                        n= 39  
No demographic data                              n= 68   
Samples used in this 
study for genotyping 
and mtDNA 
quantification 
n = 263 
Patients with SN 
n=143 
Patients without 
SN n= 120 
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2.2 SNP selection 
 
The candidate ADME genes considered in this study were those listed in Tables 1.2 and 
1.3 in chapter 1. We chose SNPs in these ADME genes to be examined in the current 
study on the basis of: 
 literature review of SNPs in these ADME genes  
  SNP MAF≥5% in Luhya of Webuye, Kenya population  
 Predicted SNP functional effect  
 Use as tag SNPs    
 If SNP assay could be designed and multiplexed successfully in 
Sequenom software. 
Due to budget constraints, we genotyped 26 SNPs. Further explanation of each of these 
criteria is provided below. 
2.2.1 Literature review of ADME genes 
 
We used NCBI Pubmed (www.ncbi.nlm.nih.gov/pubmed), OMIM (www.omim.org), 
Google Scholar (scholar.google.com), Sciencedirect (www.sciencedirect.com) and 
Ebscohost discovery (ebscohost.com) to find literature from June 2015 to March 2016 
where SNPs of interest in these genes had been previously described. SNPs of interest 
were those with: 
• Effects on ADME gene expression 
• Effects of ADME gene function 
•  Association with variable response to ART 
• Association with variable response to other drugs  
• Association with SN or any other neuropathy 
• Association with mtDNA copy number 
 
 
 
 
 38 
 
2.2.2 MAF≥5% in the LWK population 
 
Only SNPs with minor allele frequency of at least 5 % in the Luhya of Webuye, Kenya 
(LWK) population were considered. This population was used as a proxy for South African 
populations since very little whole genome data is available for SA populations (May et 
al., 2013), and furthermore it has been reported by the Bioinformatics group working with 
the South African human genome project to be more genetically similar to the bantu 
populations of south Africa. The LWK allele frequency of SNPs under consideration was 
obtained with the use of data from the 1000 Genomes project and the International Hap 
Map Project. (http://browser.1000genomes.org/index.html).  
 
The following bioinformatics tools were also used to check SNP frequencies 
 (NCBI) Variation viewer (http://www.ncbi.nlm.nih.gov/variation/view/) 
 Entire Genome Interface for Exploring SNPs (ENGINES) 
(http://spsmart.cesga.es/about.php?dataSet=engines). 
 Ensembl genome browser release 87, (http://www.ensembl.org/index.html).  
 
2.2.3 Predicted functional effect 
 
To determine the functional significance of the SNP markers we used computational tools 
SIFT (http://sift.jcvi.org) and PolyPhen 
(http://genetics.bwh.harvard.edu/pph2/index.shtml) developed to predict the potential 
functional effects of the SNPs. Both these SNP prediction tools were accessed on 
Ensembl release 86 (http://www.ensembl.org).   
 
 
 
 
 
 
 
 39 
 
2.2.4 Tag SNPs 
 
TagSNPs selection was predicted on the linkage disequilibrium (LD) between the SNPs 
emanating from the same gene, and the SNP that tagged many other SNPs was 
prioritized. The tagSNPs were generated using the Haploview (version 4.2) software from 
the HapMap data set (release 24), applying the following conditions: 
 Pairwise tagging  
 r2 =0.8 
  Minor allele frequency (MAF) greater than 5 % in the LWK population.  
 
2.2.5 Sequenom software 
 
A list of SNPs was submitted to the Mass ARRAY® Assay Designer software to confirm 
which could be multiplexed and which could not. A single multiplex PCR reaction can 
contain anywhere from a few to 40 SNPs.   
 
 
 
 
 
 
 
 
 
 
 40 
 
2.3 Genotyping using Sequenom mass-array system / -iPLEX assay 
 
A medium-throughput SNP genotyping assay, the Sequenom Mass Array ® MALDI-TOF 
MS platform using iPLEX™ Gold chemistry, was used. This service was executed by 
Inqaba Biotec (Pretoria). Basically, the Sequenom Mass Array is somewhat similar to 
Single Base Extension (SBE) sequencing assays such as SnaPshot genotyping (Applied 
Biosystems).  In the Sequenom assay, instead of single fluorescent bases being added, 
allele-specific mass is determined by mass spectrometry.  
 A total of 26 SNPs were chosen. These SNPs formed part of two multiplexes of 21 and 
33 SNPs in each multiplex which also included other SNPs being examined in our 
research group. Mass ARRAY® System Designer software was used to design a regular 
pair of PCR primers for each SNP. Forward and reverse PCR primers enabled 
amplification of the template DNA in the region spanning the SNP region of interest. PCR 
fragments were designed to be short (~100 bp regions). Mass ARRAY® System Designer 
software was also used to design the allele specific Mass EXTEND® primers for each 
SNP. The extension primers (SNPs extension primers, Appendix C) are designed to 
anneal directly adjacent to each SNP position to be assayed (http://agenabio.com). 
SNP genotyping with the Mass ARRAY System started with multiplex PCR amplification 
of short (≈100 bp) regions from template DNA. Multiplex SNP PCR was carried out in 
384-well format on an Applied Biosystems Gene Amp 9700.PCR reaction and cycling 
conditions are shown in Table 2.1.   
Next, shrimp alkaline phosphatase (SAP) was used to eliminate unincorporated 
nucleotides from the reaction. SAP protocol and temperatures are shown in Table 2.2. 
Then a mix of different extension primers (one for each SNP position to be assayed), 
modified dideoxynucleotide terminators (iPLEX termination mix) and a thermo-sequenase 
enzyme (type of Taq) were added to the amplified target DNA. PCR protocol and cycling 
conditions are shown in Table 2.3.  
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During second thermocycling, the iPLEX enzyme added one adjacent terminator to each 
extension primer. The mass differences between each of the four modified terminators 
are sufficiently large to be detected by the Mass ARRAY System.  
The arrays were placed into the matrix assisted laser desorption/ionisation time of flight 
(MALDI-TOF) mass spectrometer and the mass correlating genotypes were determined 
in real time. This occurs on a spectro-chip array loaded in to the analyser whereby the 
analyte crystals are irradiated by a laser, inducing ionisation and desorption. The time-of-
flight is proportional to mass, which correlates to allele type. The mass array has been 
created and custom-made to detect DNA with a mass range of approximately 4500 Da to 
9000 Da and can easily differentiate analytes separated by 16 Da or more. The typer 
software automatically generates reports that identify SNP alleles. This platform 
generates SNP genotypes with 99.7% accuracy. 
The generated data were viewed in the Typer Software, which provided tools that allowed 
the evaluation and management of the results (http://agenabio.com/genetics). Starting 
with the known molecular mass of the input extension primers and the four terminators, 
the data analysis software (Typer) could determine which terminator was added to each 
extension primer and thus assign the nucleotide in the SNP position (Ross et al., 1998; 
Niels and Darnhofer-Patel, 2003; Gabriel et al., 2009; Agena Bioscience, 2015 
http://agenabio.com). 
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Table 2.1 iPLEX multiplex PCR and reagents. 
iPLEX GOLD assay PCR cycling conditions and reagents 
iPLEX-multiplex PCR 
Reagent Final Concentration Volume 
Water, HPLC grade N/A 1.75 µl 
10 x PCR Buffer with  
15 mM MgCl2 
1.25x (1.875 mM MgCl2) 0.625 µl 
25 mM MgCl2 1.625 mM 0.325 µl 
25 mM dNTP Mix 500 µM 0.1 µl 
0.5 uM Primer Mix 0.1 µM 1 µl 
5 U/µl HotStar Taq 1 Unit 0.2 µl 
DNA   (5-10 ng) 1 µl 
 Total volume  5 µl 
Thermocycler cycling 
conditions 
Temperature (°C) Time Cycle/s 
 94 15 min 1 
 94 20 s  
45  56 30 s 
 72 1 min 
 72 3 min 1 
 4 ∞ 1 
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Table 2.2 iPLEX-SAP conditions and reagents. 
SAP reaction:  
Reagent  Volume  
Water, HPLC grade  1.53 µl  
SAP Buff. (10 x)  0.17 µl  
SAP Enzyme (1.7 U/µL)  0.3 µl  
 Total volume 2 µl  
Thermocycler  conditions Temperature (°C) Time 
 37 40 min 
 85 5 min 
 4 ∞ 
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Table 2.3 Primer extension cycling conditions and reagents.  
 PCR reaction:  
Reagent  Volume  
Water, HPLC grade  0.755 µl   
iPLEX buffer plus (10x)  0.2 µl  
iPLEX terminator  0.2 µl  
Primer mix  0.804 µl  
iPLEX enzyme  0.041 µl  
 Total 
volume 
          2 µl  
Thermocycler cycling 
conditions 
 Temperature  
(°C) 
Time 
 
Cycle/s 
     
  94 30 s 1 
  
 
5 X 
94 5 s   
    
40 
      
 52 5 s 
 80 5 s 
  72 180 s 1 
  4 ∞ 1 
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Figure 2.2 iPLEX assay (Agena Bioscience, iPLEX chemistry). 
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2.3.1 Quality Control of Sequenom SNP data 
 
A standard quality control measure was performed using PLINK (Purcell et al., 2007), in 
order to monitor and control the quality of our genotype data. Our protocol implemented 
QC on a “per individual” basis and subsequently on a “per marker” basis in order to 
maximize the number of markers remaining in the study. The conditions applied for both 
the categories were the following.  
i. Per individual QC 
 Identification and removal of samples with high missing genotype rates 
greater than 10 %. 
ii. Per Marker QC 
 Identification and removal of markers with a high missing genotype rates 
greater than 10 %. 
 Identification and removal of SNPs showing a significant departure from 
Hardy-Weinberg equilibrium (p<0.001). 
 Removal of all SNPs with a MAF less than 1 %. 
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2.4 qPCR assay for mtDNA copy number quantification 
 
Relative mtDNA copy number can be determined by comparing the amount of mtDNA 
present to the amount of nuclear DNA present. The mtDNA: nDNA ratio was assessed 
using qPCR and genomic (total) DNA extracted from whole blood. 
 
The PCR primers for this assay were chosen using published information for the nuclear 
(control) gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and the 
mitochondrial (target) mt-ND1 gene (see Table 2.4). Two pairs of primers per gene were 
initially chosen and used for assay optimisation. GAPDH is known to be present at single 
copy in the nuclear genome (Atema et al., 2013) and no pseudogenes of mt-ND1 are 
present in the nuclear genome (Grady et al., 2014). 
Table 2.4 PCR primers used for optimization of mtDNA copy number assay. 
Primer 
name 
Sequence (5´-3´) Length Tm, 
°C 
Direction Amplicon 
size 
 
 
 
 
Reference 
 
GAPDH1 
AAATCAAGTGGGGCGATGCTG 21 61.56 Forward 208 Zhang et 
al., 2005 
GCAGAGATGATGACCCTTTTG 21 56.95 Reverse 
GAPDH2 TGACAACGAATTTGGCTACA 20 55.60 Forward 197 Cooray 
et al., 
2002 
GGGGTCTACATGGCAACT 18 56.17 Reverse 
 
mt-NAD2A 
CTAGCCCCCATCTCAATCATA 24 63.24 Forward 
 
 Bonod-
Bidaud et 
al., 2001 
 GAATGCGGTAGTAGTTAGGAT 24 64.45 Reverse 243 
mt-NAD2B ATGGCCAACCTCCTACTCCTCATT 24 63.24 Forward 154 Psarra 
and 
Sekeris, 
2011 
 
TATGGCGTCAGCGAAGGGTTGTA 23 64.11 Reverse 
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2.4.1 Optimization of the mtDNA copy number quantification assay 
 
2.4.1.1 Endpoint PCR 
The qPCR mtDNA copy number primers in Table 2.4 were optimised using a gradient 
PCR, in order to assess specificity, determine the ideal PCR master mix protocol and 
decide on the optimal annealing temperature. This optimisation was initially performed 
using regular (endpoint) PCR. The DNA was amplified using KAPA Taq ready mix PCR 
kit (Kapa Biosystems) with a total reaction volume of 20 µl. The optimized reaction master 
mix contained the following components (Table 2.5): 
Table 2.5 PCR reaction mix 
Component 25 µl reaction Final concentration 
2X KAPA Taq Master Mix 12.5 µl 1X 
10 µM Forward primer 0.6 µl 0.24 µM 
10 µM Reverse primer 0.6 µl 0.24 µM 
Distilled water 10.3 µl N/A 
Template DNA 1 µl 0.8 ng/µl 
N\A –Not applicable 
 
A gradient PCR using a Biorad gradient thermal cycler was used for primer optimization. 
The cycling protocol for all the primers were the same except for the annealing 
temperatures. The cycling conditions consisted of an initial denaturation step at 95 °C for 
10 min followed by 30 cycles of denaturation at 95 °C for 1 min, annealing at 45 °C-50 
°C, 48 °C-54 °C for 30 s and extension at 72 °C for 1 min with a final extension step for 2 
min. 
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Agarose gel electrophoresis was used to visualize and size the PCR products and confirm 
PCR specificity. 1 % Agarose gel, prepared by weighing 0.5 g of agarose powder 
(SeaKem® LE Agarose) and dissolving it in 50 ml of 1X Tris-Borate-EDTA (TBE) buffer 
(Life Technologies or  Ambion™) was used to separate the PCR products by 
electrophoresis. The agarose powder was dissolved by microwaving in the 1X TBE buffer 
for 2-3 minutes, subsequently the liquid gel was cooled and stained with 5 µl GR green 
(Biotium) and cast on a tray to set for 15 to 20 minutes. 5 µl of the PCR products were 
loaded on to the gel by mixing it with the loading dye (Thermofisher Scientific). A DNA 
ladder (Kapa Biosystems) was used to scale the size of the bands of the PCR products.  
The agarose gels were electrophoresed for 30 minutes to an hour in 1X TBE at 100V.The 
agarose gels were visualized and images taken by Gel doc (Biorad Chemidoc MP 
system) using the Image Lab software. 
2.4.2 Optimization of qPCR  
 
PCR quantification for GAPDH and mt-ND1 genes was performed using the Light Cycler 
480 instrument II (Roche Diagnostics, Indianapolis, USA) according to the manufacturer’s 
instructions. 
2.4.2.1 Principle of the SYBR green assay 
SYBR green I is an inexpensive non-sequence specific double stranded DNA (dsDNA) 
binding fluorescent dye. SYBR green I binds randomly to any dsDNA. When SYBR green 
I is free in solution it barely fluoresces but when intercalated to a dsDNA its fluorescence 
emission increases to over a 100-fold relative to the quantity of the dsDNA present in the 
solution. After denaturation all the DNA becomes single stranded (Image a, Figure 2.3), 
SYBR is unbound and the fluorescent intensity is low. During the annealing stage the 
PCR primers hybridize to the target sequence creating small regions of dsDNA that SYBR 
green I can bind, and thereby elevating the fluorescence intensity (Image b, Figure 2.3).   
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Figure 2.3 qPCR protocol using SYBR green I (Image A-D) (Roche applied science, 2004). 
During the extension step of PCR, the primers are extended which allows more SYBR 
green I to bind (Image c, Figure 2.3). At end of the extension/elongation phase the entire 
DNA becomes dsDNA which increase the amount of SYBR green I that is bound (Image 
d, Figure 2.3).   
2.4.2.2 mtDNA: nDNA assay  
GAPDH and mt-ND1 were quantified separately, each in a 25 µl reaction volume with 0.2 
µM for the reverse and forward primer, 12.5 µl Maxima (2X) SYBR green I qPCR master 
mix (Thermo Scientific), 1 µl of 25 ng/µl DNA concentration and 10.3 µl of double distilled 
water. Amplification was carried out using a three-step-cycling protocol according to the 
specifications of the Maxima SYBR green qPCR master mix. GAPDH and mt-ND1 were 
amplified separately and two technical repeats were done for each gene. 
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Table 2.6 qPCR conditions for mtDNA: nDNA quantification. 
Step Temperature, ºC Time Number of Cycles 
Initial 
denaturation 
95 10 min 1 
Denaturation 95 15 s  
 
40 
Annealing 50 –GAPDH 
58 –mt-ND1 
30 s 
Extension 72 30 s 
Data acquisition was performed during the extension step. 
2.4.2.3 Melting curve analysis 
PCR was followed by a melting curve analysis to determine the specificity of the PCR 
reaction. The melting was performed after the amplification cycles and continued for one 
cycle at three melting temperature targets, which were:  97 ºC for 1 minute at a ramp rate 
of 4.4, 40 ºC for 10 seconds at a ramp rate 2.2 and 95 ºC acquisition mode with 5 
acquisitions per ºC at a ramp rate of 1.1.   
2.4.2.4 Standard curves 
Standard curves were used to determine the PCR efficiencies of the primers. A series of 
tenfold-dilutions was prepared using the genomic DNA from HEK293 cells starting with 
the initial concentration of 20 ng/µl yielding the following DNA dilutions 2 ng/µl, 0.2 ng/µl 
and 0.02 ng/µl. PCR efficiencies determine the amount of target DNA that is amplified per 
cycle of PCR (Svec et al., 2015). 
2.4.2.5 Crossing Points  
Crossing point (Cp) also referred to as the threshold cycle (Ct) is defined as the fractional 
cycle number or crossing point whereby the reporter dye exceeds or crosses the 
threshold point. The Cps were determined by using the second derivate maximum 
method, it is a point that correlates with the maximum of the second derivative of the 
amplification. The threshold point was determined automatically by the Roche Light 
Cycler system.  
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2.4.3 Assay validation 
 
We validated our qPCR assay using cell lines depleted of mtDNA.  It is known that 
treatment of eukaryotic cells with ethidium bromide (EtBr) depletes endogenous mtDNA 
while nDNA is maintained (creating so-called ρ0 cells devoid of mtDNA) (Seidel-Rogol 
and Shadel, 2002).  We therefore treated Human embryonic kidney (HEK) 293 cells with 
EtBr for 6 days to ensure that our assay could detect depletion of mtDNA content. 
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) high glucose 
(4.5 g/l) (Invitrogen Gibco) supplemented with 10 % fetal bovine serum, non-essential 
amino-acids and penicillin/streptomycin at 37 °C in an atmosphere humidified with 5 % 
CO2.The cells were grown to a confluence of 50-80 % prior treatment with Ethidium 
bromide (EtBr).Treatment of the cells with EtBr to hinder mtDNA replication, the cells were 
grown in the same media as described above with the presence of 50 ng/ml EtBr. The 
cells were grown for six days and harvested at three different times. The first time point 
was prior treatment (Day 0), the second time point was 48 hours post treatment (day 3) 
and the last day of harvest was 96 hours post treatment (day 6). The cells harvested were 
stored in the -20 °C freezer before DNA extractions were performed.  
DNA extraction from the HEK293 cells, from the three time-points was done using the 
DNA extraction kit (Life Technologies), following the manufacturer’s instructions, starting 
from step 8 of the protocol; protease in nuclear lysis buffer was added to the pellet of 
HEK293 cells followed by vortexing and heating at 65 ºC for 10 min in order to lyse the 
cell membrane and breakdown the proteins.  
The protein clearing solution was added to denature and remove proteins bound to the 
DNA; this was followed by incubation at  65 ºC on a heating block for 10 minutes in order 
to fully residue the crude lysate. This was followed by an incubation step at 0-5 ºC, on ice 
and centrifugation of the tube for 5 minutes at > 12,000 × g, with the DNA contained in 
the supernatant transferred to a different tube.  
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To precipitate the DNA, ice cold (0–5 °C) 90 % ethanol was added to the supernatant 
containing the DNA and the tube was inverted about 10 times and a stringy, white to 
translucent mass of DNA appeared. The DNA pellet was centrifuged at >12,000 × g for 5 
minutes followed by the removal of the supernatant, the DNA pellet was then washed 
using 70 % (v/v) ethanol and centrifuged for 1.5 minutes at >12,000 × g. The ethanol was 
then decanted and the DNA pellet was set to air dry by inverting the tube with the cap 
open over a clean lint-free disposable laboratory wipe (Kim Wipe®) for 2–3 minutes to 
evaporate the ethanol. A cotton swab was used to adsorb the residual ethanol from the 
sides and top of the tube. DNA was dissolved in sterile distilled water. To fully dissolve 
the DNA, the tube containing the DNA was placed on a heating block for 10 minutes at 
65 ºC. DNA was stored in the -20 ºC freezer.  
The DNA was quantified on the qPCR machine (Roche Diagnostics, Indianapolis, USA) 
using the method described above (2.4.2.2 and 2.4.2.5).  
2.4.4 qPCR Plate designs for cohort analysis 
 
The relative quantification of the mtDNA copy number for the 263 cohort samples was 
carried out in a total of 14 barcoded white 96-well plates (Biorad California 94547, USA) 
using optical seals for covering. Seven plates were used for the mt-ND1 gene and the 
other seven for the GAPDH gene. The arrangement for plates was as follows. 
 A series of dilutions for standard curves, this occurred in a duplicate fashion as 
two technical repeats were run for each sample to account for errors and ensure 
reproducibility of the results. 
 SN samples and/or the control samples in duplicate  
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For each sample, Ct values were obtained for each of the genes and were averaged 
across replicate wells.  The fold change in mtDNA: nDNA ratio in treated vs untreated 
samples was calculated as 2-ΔΔCt where:  
ΔCt = [Ct (target) −Ct (ref)] 
Where: 
Ct (target) = Ct value of gene of interest (mt-ND1) in untreated sample 
Ct (ref) = Ct value of control gene (GAPDH) in untreated sample. 
 
The following QC criteria were applied to the samples during data analysis: 
• All samples that had no amplification, either due to low or no DNA in respective 
wells were excluded for analysis.  
• Replicate Samples that had a Ct difference of more than 2 were excluded from 
analysis. 
• Samples with average Ct of greater than 30 for both genes (GAPDH and mt-ND1) 
were excluded for analysis.  
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2.5 Statistical analysis 
2.5.1 Demographic data and SN 
 
Statistical analyses to determine the effect of the demographic and clinical variates on 
individuals with SN (cases) and individuals (without SN) as controls were done using 
GraphPad Prism 7 software (Graphpad.com). For continuous variables a non-parametric 
Mann-Whitney test and linear regression analysis were used and the chi-squared test 
was used for categorical variables. The p-value (p<0.05) was considered to be significant 
for all the statistical tests performed in this thesis. 
 
2.5.2 mtDNA copy number analysis 
 
A non-parametric Mann-Whitney test using GraphPad Prism was used to analyse the 
statistical differences between the mtDNA/nDNA ratios in SN cases vs. controls  and 
significance was regarded as (p<0.05). 
2.5.3 SNP analysis 
 
The statistical analysis for SNPs, the construction of haplotype blocks and linkage 
disequilibrium analysis were performed using the open source software PLINK version 
1.07, with the support of the Haploview software (Purcell et al., 2007).  
PLINK is a freely available, open source whole genome association toolset widely used 
for large scale genetic association analysis. PLINK is primarily designed for analysing 
genotype/phenotype data in case-control association tests. The five domain functions of 
PLINK are data management, summary statistics, assessment of population stratification, 
association analysis and Identity by descent (IBD) estimations. PLINK is a command line 
program written in C/C++, whereby all commands involve typing at the command prompt 
(Purcell et al., 2007).  
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2.5.3.1 Allele, genotype and haplotype frequencies in the SA cohort 
 
After QC, allele and genotype frequencies in the entire cohort were calculated.  The allele 
frequencies in this South African cohort were compared to those in other African 
populations, i.e. the Luhya of Webuye, Kenyan (LWK) and the Yoruba in Ibadan, Nigerian 
populations using data from 1000 Genome phase 3 data accessible on the Ensembl 
database (Ensembl release 87, http://www.ensembl.org/index.html, January 2017).     
More than one SNP per gene was studied for the following seven genes: 
 ABCG2 (4 SNPs) 
 SLC28A1(3 SNPs) 
 SLC28A3 (2 SNPs) 
 MTHFR (2 SNPs)  
 RRM1 (4 SNPs) 
 TK2 (3 SNPs) 
 SAMHD1 (3 SNPs) 
 
Haplotypes and LD across SNPs of these genes were examined using PLINK version 
1.07 (Purcell et al., 2007) and Haploview version 4.2 (Barret et al., 2005). Pairwise 
linkage disequilibrium of genes with more than one SNP genotyped was calculated. 
SNPs were considered to be in LD if R2 ≥ 0.2 and were less than 500 Kb apart. The 
files PLINK.info and PLINK.ped generated through PLINK were used on the 
Haploview software to create a graphical representation of the LD pairwise 
calculations. Haplotypes for the SNPs were constructed and their frequencies 
estimated using the sliding window specification approach in PLINK. 
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2.5.3.2 Association analysis with phenotypes 
 
PLINK was used to look for associations between candidate SNPs and phenotypes, and 
the phenotypes considered included: 
• SN ever – sensory neuropathy ever was defined as having at least one sign 
and at least one symptom of sensory neuropathy as outlined in the brief peripheral 
neuropathy screening tool from the AIDS Clinical Trials Group (ACTG) (Chery et 
al., 2005), during the time of screening or at previous times. 
•  mtDNA copy number- mtDNA copy number phenotype was taken as a 
ratio between mitochondrial gene copies cross points and the nuclear gene copies 
cross points from qPCR assay  (mtDNA: nDNA). 
• CD4+ T-cell count (current) – CD4+ T-cell count was the number of CD4+ 
T-cells per microliter (cells/µl) of the blood sample at the time of sample collection. 
The SNP association analyses were carried out using both univariate and multivariate 
analysis. All 26 SNPs were tested for association with the phenotype in both univariate 
and multivariate analysis.  
2.5.3.2.1 Univariate analysis 
 
The association of individual SNPs with phenotype data such as SN-ever, or mtDNA copy 
number or CD4+ T-cell count were analysed using the univariate data analysis method. 
The empirical tests that we have used in this study are the following. 
 Allelic test 
 Genotypic (2 df) test 
 Dominant gene action (1df) test 
 Recessive gene action (1df) test 
 Haplotype association test  
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Three different genotypic models of inheritance were assessed as follows: The dominant 
model assessed having at least one minor allele versus not having any minor allele, the 
recessive model assessed having two minor alleles versus having at least one major 
allele, and the codominant model assessed all genotypes separately (Table 2.7). 
Empirical p-values (pEMP) were generated by PLINK, using a Monte Carlo-based max 
(T) permutation testing method. A hundred thousand simulations were performed. PLINK 
generated both uncorrected (EMP1) and corrected (EMP2) empirical p-values. The 
corrected empirical p-value (EMP2) does not assume that the tests are independent, but 
it still controls the probability of observing at least one false positive per experiment and 
hence is more stringent than the conventional EMP1 p-value. In both cases, p-values of 
<0.05 were taken as significant (Hider et al., 2008). 
Table 2.7 Allelic and Genotypic models used in association tests. 
Test    
Allelic: D versus               d 
Dominant: (DD, Dd) versus         dd 
Recessive: DD versus   (Dd, dd) 
Genotypic: or 
codominant 
DD versus Dd     versus    dd 
                                        ‘’D’’- Minor allele and ‘’d’’ Major allele 
2.5.3.2.2 Multivariate analysis 
Two demographic factors which were significantly associated with SN (age and height) 
were used as covariates in multivariate analyses of SNP association with sensory 
neuropathy.   
One clinical variable which was significantly associated with CD4+ T cell count (number 
of months HIV+) was used as a covariate in the multivariate analysis of SNP association 
with CD4+ T cell count.   
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No demographic or clinical covariates were identified as associating with mtDNA copy 
number, therefore multivariate analysis of association between genetic variation and 
mtDNA copy was not performed.  
A SNP-based logistic regression was used for the association analysis with sensory 
neuropathy ever (SN), as it is presented as a dichotomous phenotype in our study. Linear 
regression models for continuous traits (quantitative) were used for SNP associations 
with phenotypes CD4+ T cell count and mtDNA copy number.  
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CHAPTER 3 
RESULTS 
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CHAPTER 3: RESULTS 
3.1 Demographic and clinical data and their association with sensory neuropathy 
and CD4+ T cell count 
 
Two hundred and sixty-three (n= 263) Black adult participants of African descent were 
enrolled in this study, 205 (78 %) were female and 58 (22 %) were male. The participants 
were all from southern African countries with over 95 % of the participants being South 
Africans from all the 9 indigenous ethnic groups in South Africa (Venda, Zulu, Pedi, Sotho, 
Tswana, Swati, Tsonga, Xhosa, and Ndebele) with the other remaining participants from 
the Niger-Kordofanian-speaking countries (Zimbabwe, Mozambique, Malawi).   
 
The demographic and clinical differences between those with sensory neuropathy (SN) 
and those without SN were analysed. The prevalence of SN was not associated with the 
following clinical variables: CD4+ T cell count at time of sample collection;  CD4+ T cell 
count nadir, number of months HIV+ and demographic variables; gender, weight and BMI. 
Height and age were significantly associated with sensory neuropathy during the 
univariate evaluation between SN and SN-free individuals, with p<0.0001 and p<0.007 
respectively, as per Table 3.1. The mean (range) height for all the participants was 158 
cm (132-186.6) with the cases (with SN) having a mean of 159.4 cm and the mean for 
the control group (without SN) 156.4 cm. The mean age of the participants was 40.5 (20-
58) years for the cases and 35.86 (19-59) years for the controls. 
 
Descriptive statistics for the cohorts used in this study are provided in Table 3.1, with 
females representing 77 % and 79 % of the SN cases and controls respectively. The 
CD4+ T cell count was generally high post-ART with a mean (range) of 429.2 (0-1091) 
cells per mm3.  
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Table 3.1 Associations between demographic and clinical factors with SN. 
  
(Red) p<0.05 significantly associated with sensory neuropathy. 
-- Not applicable/No data. 
All the other p-value tests were obtained using the t-test non-parametric Mann Whitney test. 
 
 
 
 
 
Demographic 
description 
Cases 
with SN 
Controls 
without SN 
Total p-value 
Sample Size 143 120 263 - 
Female 110 (77 %) 95 (79 %) 205 (78 %) 0.333 
Age in years 
Mean 
40.5 35.86 38.38 <0.0001 
 
Height in cm 
Mean 
159.4 156.4 158.1 0.007 
 
Weight in kg 
Mean 
69.56 67.49 68.61 0.231 
Body mass index (BMI) 
Mean 
27.45 27.66 27.55 0.970 
Months since HIV 
diagnosis 
Mean 
53.58  49.32 51.63 0.538 
CD4 count (current) 
Mean  
432.5 425.3 428.9 0.392 
CD4 count (nadir) 
Mean  
86.7 94.16 90.1 0.343 
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None of the demographic data was significantly associated with mtDNA copy number in 
our study cohort as shown by Table 3.2. 
Therefore no covariates were identified that needed to be taken into account in 
multivariate analyses of genetic variation associated with mtDNA copy number.  
Table 3.2 Association of demographic data with mtDNA copy number. 
 
Demographic variable p-value 
Age     0.470  
Height (cm)   0.947  
CD4 Nadir (cells.mm3)  0.409  
Gender (%)  0.251  
CD4 at Sampling (cells.mm3)  0.515  
Months HIV-positive   0.414  
Months on d4T  0.773  
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After performing linear regression analyses between CD4+ T cell count and clinical and 
demographic variables only the number of months HIV+ emerged as an independent 
variable associated with CD4+ T cell count (p<0.0001).  
The demographic variables not associated with CD4+ T cell count were age, height, 
weight, BMI and the clinical variable CD4+ T cell count (nadir).  
 
Table 3.3 Associations between demographic and clinical variables with CD4+T 
cell counts at time of sample collection.  
 
Demographic 
description 
n/mean p-value R-square 
Size (n) 263 - - 
Female (n) 205 - - 
Age (years) 38.38 0.097 0.011 
Height (cm) 158.1 0.911 0.00005 
BMI (kg/m2) 
mean 
27.55 0.286 0.004 
Weight (kg) 
mean 
68.61 0.2704 0.005 
CD4+ count nadir 
(cells\mm3) 
90.1 0.264 0.005 
Months HIV+ 
mean 
51.63 <0.0001 0.102 
                               -- Not applicable/No data. 
                               (Bold) p<0.05 significantly associated with CD4 count restitution.
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3.2 Cohort DNA Quantification  
 
The cohort DNA samples had high yield DNA concentrations with the lowest having the 
concentration of 56.59 ng/µl and the highest being 2395.20 ng/µl with the average 
concentration for all the cohort samples at 494, 33 ng/µl. Good quality DNA has A260/280 
ratio between 1.7-2.0, the cohort samples had A260/280 ratio averaging 1.70 which is 
highly acceptable and regarded as pure and suitable for further downstream applications. 
3.3 SNP Choice 
 
We chose SNPs in candidate ADME genes to be examined in the current study on the 
basis of the criteria below as described in the Methods section: 
 literature review of SNPs  
 MAF≥ 5 % in Luhya of Webuye, Kenya population in 1000 
genomes and HapMap data 
 Predicted functional effect  
 Use as tag SNPs    
 If the SNP assay could be designed and multiplexed successfully in 
the Mass ARRAY designer PCR software. 
The SNPs were prioritized based on meeting the majority of the criteria, with the 
ability of the SNP assay and multiplex as the cut-off point.   
Results showing many interesting SNPs meeting these criteria are summarised in the 
Table 3.4 below. From this list, a total of 26 SNPs were finally chosen for genotyping in 
the Sequenom Mass ARRAY iPLEX genotyping platform.
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Table 3.4 SNPs of interest meeting our criteria for SNP selection, with 26 indicated by * selected for genotyping. 
Gene SNP  Predicted effect on 
function.  
Function Reference MAF 
in 
LWK 
Tag 
SNP 
  SIFT PolyPhen   
SLC28A1 rs2290272* Tolerated Benign Reduced expression and lowered affinity for 
substrates. 
Kroetz, Yee and 
Giacomini, 2010 
0.172 Tag (3) 
SLC28A1 rs2242046* Tolerated Benign A synonymous variant resulting in amino-acid 
change from aspartate to asparagine that is 
associated with dose-toxicity of zidovudine. 
Tekola-Ayele et 
al., 2015 
0.06 Tag (1) 
SLC28A1 rs8187758* 
 
Tolerated Possibly 
damaging 
A missense variant, increases thymidine uptake. - 0.131 Not tag 
SLC28A3 rs4877847* - - An intron variant; loss of function for the influx 
transporter. 
Visscher et al., 
2011 
0.438 Tag (3) 
SLC28A3 rs7853758* - - A synonymous variant; predictive of 
anthracycline-induced cardiotoxicity and 
reduced SLC28A3 mRNA expression. 
Visscher et al., 
2011 
0.32 Tag (6) 
ABCC5 rs3749442* - - Associated with vincristine-induced peripheral 
neuropathy. 
Broyl et al., 2010 0.237 Tag (45) 
ABCG2 rs2725252* - - An intron variant; affects mRNA expression of 
ABCG2.  
Delord et al., 
2013 
0.206 Not tag 
ABCG2 rs12505410* - - An intron variant; affects mRNA expression of 
ABCG2.  
Delord et al., 
2013 
0.126 Not tag 
ABCG2 rs3114018* - - Associated with severe oxaliplatin-induced 
peripheral neuropathy. 
Custodio et al., 
2014 
0.333 Not tag 
ABCG2 rs2622604* - - Reduced ABCG2 (BCRP) mRNA expression. Cha et al.,2009 0.126 Tag (7) 
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Table 3.4 continued. SNPs of interest meeting our criteria for SNP selection, with 26 indicated by * selected for 
genotyping. 
Gene SNP  Predicted effect on 
function 
 
Function Reference MAF 
in 
LWK 
Tag 
SNP 
 SIFT Polyphen   
RRM1 rs12806698* 
 
- - Associated with expression levels. Cao et al.,2013 0.015 Tag(1) 
RRM1 rs1465952* 
 
- - Associated with expression levels.  Cao et al.,2013 0.361 Tag (18) 
RRM1 rs11030918* - - Associated with expression levels.  Cao et al.,2013 0.189 Not tag 
RRM1 rs1042927* - - Associated with expression levels.  Cao et al.,2013 0.232 Tag (73) 
RRM1 rs1561786nt 
 
- - Promoter SNP associated with lower levels of 
RRM1 gene expression. 
Cao et al.,2013 0.026 Tag (3) 
RRM2B rs16918482* - - 3'UTR variant. - 0.076 Tag (25) 
MTHFR rs1801131* 
. 
Tolerated Benign Decreased activity of MTHFR; associated 
with SN and pancreatitis. 
Domingo et al., 
2013a 
0.175 Tag (2) 
MTHFR rs1801133* Deleterious Possibly 
damaging 
Decreased activity of MTHFR; associated 
with SN and pancreatitis. 
Domingo et al., 
2013a 
0.133 Not tag 
TK2 rs3743712* 
 
- - Affects TK2 expression, 3'-UTR variant. Gamazon et al., 
2012 
0.369 Tag (15) 
TK2 rs11859474* - - An intron variant. - 0.293 Tag (33) 
TK2 rs2288399* - - An intron variant. - 0.08 Tag (23) 
DHFR rs1650723* 
 
- - An upstream gene variant. - 0.071 Tag (7) 
SLCA19  rs1051266* Tolerated Benign A missense variant, associated response to 
methotrexate. 
de Rotte et al., 
2012 
0.308 Tag (6) 
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Table 3.4 continued. SNPs of interest meeting our criteria for SNP selection, with 26 indicated by * selected for 
genotyping. 
Gene SNP  Predicted effect on 
function  
Function Reference MAF 
in 
LWK 
Tag 
SNP 
 SIFT PolyPhen   
SAMHD1 rs1291142* - - An intron variant, affects mRNA expression. Coon and Wang, 
2012 
0.237 Tag (19) 
SAMHD1 rs1891643* 
 
- - An intron variant. - 0.207 Tag (12) 
SAMHD1 rs8124728* 
 
- - 3'UTR variant. 
 
- 0.152 Tag (3) 
RRM2 rs7574663* - - Promoter SNP associated with levels of RRM2 
gene expression. 
Cao et al.,2013 0.16 Tag (4) 
ABCC5 rs3749445nt - - oxaplatin response , 3'UTR - 0.121 Tag (2) 
ABCC5 rs562nt - - 3' UTR; irinotecan-toxicity. - 0.343 Not tag 
ABCC5 rs939336nt - - - - 0.278 Tag (32) 
ABCG2 rs2231137nt  Tolerated Benign Reduced level of protein, decreased enzyme 
activity. 
Hampras et al., 
2010 
0.116 Tag (1) 
ABCG2 rs7699188nt - - Predicted to result in the gain of an HNF4 site. Rudin et al.,2016 0.407 Tag (24) 
SLC28A3 rs56350726nt  Deleterious Possibly 
damaging 
Associated with gemcitabine toxicity. - 
 
0.07 Tag (5) 
SLC28A3 rs10868138nt Deleterious Benign Associated with gemcitabine toxicity. - 0.17 Tag (3) 
*genotyped  
 nt = not genotyped in this study 
  “-“score not applicable  
 MAF = minor allele frequency 
 LWK = Luhya of Webuye, Kenya
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3.4 Sequenom Results 
  
Figure 3.1 shows an example of a Mass Array spectrum multiplexing some of the 
candidate SNPs chosen for genotyping in this study. From this Mass Array Spectrum, 
using the Typer Software a report was generated which was able to distinguish between 
SNP alleles within each sample interrogated. Here SNP rs9905016 from POLG 2 was 
used as an example. Figure 3.2 shows an example of an rs9905016 heterozygous 
sample with two peaks at 5330 and 5410 Da respectively while Figure 3.3 shows an 
example of an rs9905016 homozygous sample with only one peak at 5330 Da. 
 
 
Figure 3.1 Mass spectrums for all the SNPs in the multiplex reaction. 
 
 
 
 
Figure 3.2 Example of mass spectrum for rs9905016 Heterozygote, with two peaks at 5330 and 5410 Da 
respectively. 
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Figure 3.3 Example of mass spectrum for rs9905016 homozygote with only one peak at 5330 Da. 
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3.4.1 Minor allele frequencies in the SA population 
After QC 243 samples remained (120 controls and 143 cases) with a genotyping rate of 
99%. The minor allele frequencies (MAFs) in the cohort were calculated using the PLINK 
toolset, for the 26 SNPs genotyped and all of the SNPs had a frequency greater than 1 
% (See Table 3.5). All the 26 SNPs were in Hardy –Weinberg equilibrium after comparing 
the genotype expected and observed p-values in the cases and controls. All the SNPs 
passed the genotype missingness test set to exclude all SNPs missing 10 % of the 
genotypes. The RRM1 gene SNP rs12806698 allele (A>C) had the lowest frequency 
0.021 in the current study.  
The MTHFR SNPs allele frequencies as discovered by Scholtz et al. (2002) in a black 
population that comprised of three SA ethnic groups of Zulu, Pedi and Xhosa differed 
significantly to the allele frequencies that we reported in this study, at 0.04 vs. 0.07 and 
0.09 vs. 0.144 for SNP rs1801133 and rs1801131 respectively.  
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Table 3.5 Minor allele frequencies (MAFs) for d4T transporter genes and dNTP 
regulator genes in the SA cohort. 
Chra Gene SNP ID Positionb A1c A2c SA MAFd 
d4T transporter genes 
3 ABCC5 rs3749442 183942797 A G 0.208 
4 ABCG2 rs2725252 88140758 A C 0.193 
4 ABCG2 rs2622604 88157772 T C 0.132 
4 ABCG2 rs12505410 88109689 G T 0.122 
4 ABCG2 rs3114018 88143429 C A 0.419 
9 SLC28A3 rs4877847 84331502 C A 0.469 
9 SLC28A3 rs7853758 84286011 A G 0.5 
15 SLC28A1 rs2242046 84935498 A G 0.025 
15 SLC28A1 rs2290272 84904200 A G 0.242 
15 SLC28A1 rs8187758 84905644 A C 0.155 
dNTP pool regulator genes 
1 MTHFR rs1801131 11794419 G     T 0.144 
1 MTHFR rs1801133 11796321 A     G 0.070 
2 RRM2 rs7574663 10119200 G     C 0.084 
5 DHFR rs1650723 80626211 T     C 0.062 
8 RRM2B rs16918482 102206460 C     A 0.064 
11 RRM1 rs1465952 4093309 A     G 0.477 
11 RRM1 rs11030918 4094257 C     T 0.200 
11 RRM1 rs12806698 4094744 A     C 0.021 
11 RRM1 rs1042927 4138699 C     A 0.181 
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Table 3.5 continued. Minor allele frequencies (MAFs) for d4T transporter genes and 
dNTP regulator genes in the SA cohort. 
Chra Gene SNP ID Positionb A1c A2c SA MAFd 
16 TK2 rs3743712 66509747 G     A 0.391 
16 TK2 rs11859474 66520637 A G 0.263 
16 TK2 rs2288399 66531589 G     A 0.152 
20 SAMHD1 rs8124728 36892303 A     G 0.169 
20 SAMHD1 rs1291142 36896959 G     A 0.231 
20 SAMHD1 rs1891643 36941608 G     A 0.187 
21 SLC19A1 rs1051266 45537880 C T 0.311 
a Chromosome number 
b Position of the SNP on the corresponding chromosome number as prescribed by the Ensembl database. 
c Alleles assigned by 1000 genomes phase 3 database. 
dThe MAF from the Southern African population data (cohort samples genotyped in this study).   
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3.4.2 Minor allele frequencies in SA vs other African populations 
 
The minor allele frequencies for the Southern African cohort for 26 SNPs were compared 
with the MAF in other African populations, the LWK population and the YRI population 
(Table 3.6). The LWK and the YRI are the two population groups which are often used 
as the reference population for the Southern African population due to a paucity of allele 
frequency distribution for the local population groups.  This is because these three 
populations are thought to share recent common ancestry with via the expansion of 
Bantu-speaking groups within the last 5000 years (May et al. 2013). 
Several alleles in transporter genes were significantly different in frequency among the 
three populations, while none of the alleles in genes of the thymidine synthesis / 
metabolism pathway were significantly different in frequency among the three 
populations. This shows that the YRI and LWK are not always good proxies for genetic 
data in SA populations 
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Table 3.6 The comparison of minor allele frequencies of the SA population with 
MAF of other African populations. Significant p values (p<0.05) shown in red bold.  
 
Gene SNP Positionb Minor allele frequenciesc p-value 
SA LWK YRI  
d4T transporter genes  
ABCC5 rs3749442 183942797 0.208 0.237 0.194 0.640 
ABCG2 rs2725252 88140758 0.193 0.222 0.333 0.002 
ABCG2 rs2622604 88157772 0.132 0.126 0.083 0.217 
ABCG2 rs12505410 88109689 0.122 0.126 0.06 0.039 
ABCG2 rs3114018 88143429 0.419 0.333 0.31 0.035 
SLC28A3 rs4877847 84331502 0.470 0.475 0.463 0.9698 
SLC28A3 rs7853758 84286011 0.5 0.303 0.366 0.0001 
SLC28A1 rs2242046 84935498 0.025 0.061 0.000 0.0008 
SLC28A1 rs2290272 84904200 0.242 0.172 0.171 0.059 
SLC28A1 rs8187758 84905644 0.155 0.131 0.157 0.700 
dNTP pool regulator genes  
MTHFR rs1801131 11794419 0.144 0.187 0.120 0.159 
MTHFR rs1801133 11796321 0.070 0.071 0.106 0.284 
RRM2 rs7574663 10119200 0.084 0.146 0.134 0.081 
DHFR rs1650723 80626211 0.062 0.071 0.046 0.565 
RRM2B rs16918482 102206460 0.064 0.076 0.065 0.889 
RRM1 rs1465952 4093309 0.477 0.389 0.449 0.170 
RRM1 rs11030918 4094257 0.20 0.167 0.181 0.632 
RRM1 rs12806698 4094744 0.021 0.015 0.019 0.914 
RRM1 rs1042927 4138699 0.181 0.263 0.190 0.079 
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Table 3.6 continued. The comparison of minor allele frequencies of the SA 
population with MAF of other African populations. Significant p values (p<0.05) 
shown in red bold. 
Gene SNP Positionb Minor allele frequenciesc p-value 
   SA LWK YRI  
TK2 rs11859474 66520637 0.263 0.293 0.278 0.518 
TK2 rs2288399 66531589 0.152 0.081 0.106 0.058 
SAMHD1 rs8124728 36892303 0.169 0.152 0.148 0.808 
SAMHD1 rs1291142 36896959 0.231 0.237 0.231 0.984 
SAMHD1 rs1891643 36941608 0.187 0.207 0.167 0.572 
SLC19A1 rs1051266 45537880 0.311 0.308 0.329 0.892 
a Chromosome numbers for SNPs. 
b Position of the single nucleotide polymorphism on the respective chromosome. 
c Minor allele frequencies for the LWK and YRI population from a 1000 genomes phase 3 database 
published on Ensembl.  
(Red) p<0.05 significantly different from each other. 
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3.4.3 LD and Haplotype analyses in the SA cohort.  
 
Linkage disequilibrium (LD) was analysed for seven genes with more than one SNP 
genotyped (ABCG2, SLC28A1, SLC28A3, MTHFR, RRM1, TK2 and SAMHD1).  SNPs in 
five of these genes showed strong linkage between the following polymorphisms: 
RRM1: strong LD between rs1465952, rs11030918 and rs12806698 (Fig 3.4); 
TK2: strong LD between rs3743712 and rs11859474 (D’= 1.000) (Fig 3.5); 
SAMHD1: complete linkage between all three SNPs rs8124728, rs1291142 and 
rs1891643 (D’= 1.000) (Fig 3.6); SLC28A1: strong LD between s2290272 and rs8187758 
(D’= 0.961) (Fig 3.7). 
 
ABCG2: strong LD between rs12505410 and rs2725252 (D’= 1.000) (Fig 3.8).    
The following SNPs from MTHFR rs1801131 and rs1801133 (D’= 0.009) and SLC28A3 
rs4877847 and rs7853758 (D’= 0.253) were not in significant LD with each other. 
 
 
Figure 3.4 RRM1 gene LD plot generated using Haploview. The red blocks on the LD plot depicted in this 
figure and those below indicate the strength of the LD, with the brighter the square the higher the LD and 
fainter red the lower the LD.   
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Figure 3.5 TK2 gene LD plot generated using Haploview. 
 
 
Figure 3.6 SAMHD1 gene LD plot generated using Haploview.   
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Figure 3.7 SLC28A1 gene LD plot generated using Haploview. 
 
 
Figure 3.8 ABCG2 gene LD plot generated using Haploview. 
 
The frequencies of two and three-SNP haplotypes in the seven genes were calculated 
using the sliding window specification approach in PLINK. There were 42 haplotype 
combinations created from 7 genes (ABCG2, SAMHD1, SLC28A1, SLC28A3, MTHFR, 
TK2 and RRM1), with 34 haplotypes derived from three-SNP combinations whereas 8 
haplotypes were derived from two-SNP combinations (Table 3.7).  
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Table 3.7 Haplotype frequencies in the SA cohort. 
 
 
 
 
Gene Haplotype Frequency 
 
loci in the haplotype 
MTHFR GA 0.011 rs1801131|rs1801133 
 TA 0.059 rs1801131|rs1801133 
 GG 0.133 rs1801131|rs1801133 
 TG 0.797 rs1801131|rs1801133 
ABCG2 TAC 0.101      rs12505410|rs2725252|rs3114018 
 GCC 0.099   rs12505410|rs2725252|rs3114018 
 TCC 0.219   rs12505410|rs2725252|rs3114018 
 TAA 0.092 rs12505410|rs2725252|rs3114018 
 GCA 0.024 rs12505410|rs2725252|rs3114018 
 TCA 0.465 rs12505410|rs2725252|rs3114018 
 CCT 0.022 rs2725252|rs3114018|rs2622604 
 CAT 0.104 rs2725252|rs3114018|rs2622604 
 ACC 0.095 rs2725252|rs3114018|rs2622604 
 CCC 0.297 rs2725252|rs3114018|rs2622604 
 AAC 0.094 rs2725252|rs3114018|rs2622604 
 CAC 0.383 rs2725252|rs3114018|rs2622604 
SLC28A3 AC 0.174 rs7853758|rs4877847 
 GC 0.295 rs7853758|rs4877847 
 AA 0.323 rs7853758|rs4877847 
 GA 0.208 rs7853758|rs4877847 
RRM1 ACA 0.021 rs1465952|rs11030918|rs12806698 
 ACC 0.18 rs1465952|rs11030918|rs12806698 
 ATC 0.277 rs1465952|rs11030918|rs12806698 
 GTC 0.522 rs1465952|rs11030918|rs12806698 
 CCC 0.041 rs11030918|rs12806698|rs1042927 
 TCC 0.135 rs11030918|rs12806698|rs1042927 
 CAA 0.016 rs11030918|rs12806698|rs1042927 
 CCA 0.139 rs11030918|rs12806698|rs1042927 
 TCA 0.664 rs11030918|rs12806698|rs1042927 
SLC28A1 GCA 0.012 rs2290272|rs8187758Â |rs2242046 
 AAG 0.149 rs2290272|rs8187758Â |rs2242046 
 ACG 0.079 rs2290272|rs8187758Â |rs2242046 
 GCG 0.743 rs2290272|rs8187758Â |rs2242046 
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Table 3.7 continued. Haplotype frequencies in the SA cohort. 
 
3.4.4 SNP Genotype frequencies in SA population 
 
The determination of the genotypes for all the 26 SNPs in 243 DNA samples in this study 
allowed for the subsequent determination of the genotype frequencies for the Southern 
African population. The Chi-square test of observed versus expected genotype 
frequencies was conducted and all the genotypes were found to be in Hardy-Weinberg 
equilibrium (Appendix B).  
 
 
 
 
 
 
 
Gene Haplotype Frequency 
 
loci in the haplotype 
TK2 GGG 0.11 rs3743712|rs11859474|rs2288399 
 AGG 0.042 rs3743712|rs11859474|rs2288399 
 GAA 0.263 rs3743712|rs11859474|rs2288399 
 GGA 0.017 rs3743712|rs11859474|rs2288399 
 AGA 0.567 rs3743712|rs11859474|rs2288399 
SAMHD1 GGG 0.187 rs8124728|rs1291142|rs1891643 
 GGA 0.045 rs8124728|rs1291142|rs1891643 
 AAA 0.169 rs8124728|rs1291142|rs1891643 
 GAA 0.598 rs8124728|rs1291142|rs1891643 
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3.5 Associations between SNPs and sensory neuropathy.  
 
A total of 26 SNPs, including ten SNPs from four drug transporter genes and 16 SNPs 
from eight dNTP pool regulator genes were used to analyse association with sensory 
neuropathy (SN) using univariate and multivariate analysis methods.  
3.5.1 Univariate SNP association with SN 
 
The single SNP univariate analyses for association with SN was done using PLINK using 
the allelic and three genotype models (genotypic, dominant and recessive). 
 
Only one SNP of the SLC28A1 transporter gene (709C>A; rs8187758) was found to be 
significantly associated with sensory neuropathy. This SNP was significantly associated 
with sensory neuropathy in the genotypic model test PEMP1<0.05 at p=0.026, but not 
significant for the PEMP2<0.05 correction for multiple testing. No association was found 
for all the other models tested (allelic, dominant and recessive) (Table 3.8, highlighted.) 
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Table 3.8 Univariate analyses of association of alleles and genotypes with sensory neuropathy. Significant p-
values (p<0.05) highlighted in red.  
(Red) p<0.05 Significant association with sensory neuropathy.  
  
Univariate analyses for association of alleles and genotypes with sensory neuropathy. 
Gene SNP Allelic Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
Drug transporters genes 
ABCC5 rs3749442 0.255 0.998 0.351 1.000 0.425 1.000 0.194 0.955 
 
ABCG2 
rs12505410 0.159 0.976 0.327 1.000 0.136 0.978 0.876 1.000 
rs2725252 0.908 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
rs3114018 0.284 1.000 0.559 1.000 0.398 1.000 0.314 0.999 
rs2622604 0.535 1.000 0.867 1.000 0.507 1.000 0.791 1.000 
 
SLC28A3 
rs7853758 0.782 1.000 0.913 1.000 0.655 1.000 1.000 1.000 
rs4877847 0.748 1.000 0.428 1.000 0.350 1.000 0.641 1.000 
 
SLC28A1 
rs2290272 0.174 0.991 0.154 0.981 0.082 0.855 0.810 1.000 
rs8187758 0.226 0.998 0.026 0.458 0.061 0.731 0.193 0.978 
rs2242046 0.235 0.997 0.236 0.998 0.238 0.997 1.000 1.000 
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Table 3.8 continued.  Univariate analyses of association of alleles and genotypes with sensory neuropathy.  
dNTP pool regulators genes 
Gene SNP Allelic Genotypic Dominant Recessive 
  PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
MTHFR rs1801131 0.239 0.997 0.376 1.000 0.383 1.000 0.329 0.999 
rs1801133 1.000 1.000 0.917 1.000 1.000 1.000 1.000 1.000 
RRM2 rs7574663 0.629 1.000 0.861 1.000 0.604 1.000 1.000 1.000 
DHFR rs1650723 0.847 1.000 0.846 1.000 0.846 1.000 1.000 1.000 
RRM2B rs16918482 0.722 1.000 0.919 1.000 0.843 1.000 0.78 1.000 
RRM1 rs1465952 0.930 1.000 0.864 1.000 0.950 1.000 0.716 1.000 
rs11030918 0.420 1.000 0.415 1.000 0.688 1.000 0.141 0.941 
rs12806698 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
rs1042927 0.701 1.000 0.829 1.000 0.685 1.000 1.000 1.000 
 
TK2 
rs3743712 0.527 1.000 0.493 1.000 0.315 1.000 1.000 1.000 
rs11859474 0.920 1.000 0.424 1.000 0.518 1.000 0.484 1.000 
rs2288399 0.905 1.000 0.774 1.000 1.000 1.000 0.521 1.000 
 
SAMHD1 
rs8124728 0.720 1.000 0.055 0.746 0.263 0.999 0.108 0.863 
rs1291142 0.332 1.000 0.246 1.000 0.170 0.987 0.684 1.000 
rs1891643 1.000 1.000 0.372 1.000 0.685 1.000 0.301 0.997 
SLC19A1 rs1051266 0.186 0.991 0.328 1.000 0.157 0.972 0.815 1.000 
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3.5.2 Multivariate analysis of SNP association with SN. 
 
Next multivariate analysis using logistic regression was performed taking into account two 
demographic covariates (age and height) simultaneously. All SNPs were analysed during 
multivariate analysis, regardless of significance status during univariate testing.  The 
analysis deployed four tests which were the allelic test and three genotype tests 
(dominant, recessive and genotypic/co-dominant). 
 
Alleles and or genotypes of four SNPs from the d4T metabolism / dNTP regulation 
pathways were associated with SN in the multivariate analysis after correcting for age 
and height, but before correction for multiple testing (Table 3.9) as follows: 
 
MTHFR rs1801131: this missense variant was associated with SN after correcting for 
age and height, in genotypic and recessive models, with point-wise estimates (PEMP1), 
p=0.001 and p=0.001 respectively. The corrected (PEMP2) values were not significant.  
RRM2B rs16918482 : this 3’ UTR variant was found to be associated with SN after 
correcting for age and height, in genotypic and recessive models, with point-wise 
estimates (PEMP1), p=0.001 and p=0.00001 respectively. The correction values 
(PEMP2) were not significant for all the tests.  
SAMHD1 rs8124728: this 3’ UTR variant was found to be associated with SN after 
correcting for age and height, in genotypic and recessive model with  the point-wise 
estimates (PEMP1), p=0.017 and p=0.015 respectively. The correction values (PEMP2) 
were not significant for all the tests. 
 SAMHD1 rs1891643: this intron variant was found to be associated with SN after 
correcting for age and height, in the recessive test for the point-wise estimate (PEMP1), 
p= 0.027 with correction (PEMP2) not significant for all the tests. 
 
None of these SNPs or genotypes were significantly associated with SN in a multivariate 
model after correction for multiple testing (all PEMP2 values >0.05, Table 3.9).
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Table 3.9 Multivariate analysis of SNP association with d4T-induced sensory neuropathy; age and height were 
used as covariates. Significant p-values (p<0.05) highlighted in red. 
Multivariate logistic regression analysis for association with d4T-induced sensory neuropathy. 
Gene SNP Allelic Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
Drug transporter genes 
ABCC5 rs3749442 0.370 1.000 0.262 0.986 0.551 1.000 0.3000 0.989 
 
ABCG2 
 
rs12505410 0.159 0.984 0.698 1.000 0.149 0.974 0.746 1.000 
rs2725252 0.885 1.000 0.829 1.000 0.957 1.000 0.866 1.000 
rs3114018 0.272 0.999 0.317 1.000 0.284 1.000 0.508 1.000 
rs2622604 0.392 1.000 0.319 1.000 0.492 1.000 0.330 1.000 
 
SLC28A3 
rs7853758 0.606 1.000 0.609 1.000 0.544 1.000 0.822 1.000 
rs4877847 0.468 1.000 0.521 1.000 0.213 0.997 0.913 1.000 
 
SLC28A1 
 
rs2290272 0.28 1.000 0.892 1.000 0.126 0.961 0.558 1.000 
rs8187758 0.410 1.000 0.171 0.975 0.144 1.000 0.073 0.923 
rs2242046 0.240 1.000 1.000 1.000 0.242 1.000 1.000 1.000 
(Red Bold) p<0.05 Significant association with sensory neuropathy.  
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Table 3.9 continued. Multivariate analysis of SNP association with d4T-induced sensory neuropathy; age and 
height were used as covariates. Significant p-values (p<0.05) highlighted in red.  
dNTP pool regulator genes 
Gene SNP Allelic Genotypic Dominant Recessive 
  PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
MTHFR rs1801131 0.134 0.968 0.001 0.852 0.239 0.998 0.002 0.875 
rs1801133 0.996 1.000 0.438 1.000 0.853 1.000 0.443 1.000 
RRM2 rs7574663 0.434 1.000 0.477 1.000 0.389 1.000 0.40 1.000 
DHFR rs1650723 0.801 1.000 1.000 1.000 0.801 1.000 1.000 1.000 
RRM2B rs16918482 0.881 1.000 0.001 1.000 0.940 1.000 0.00001 1.000 
 
 
RRM1 
rs1465952 0.936 1.000 0.973 1.000 0.552 1.000 0.619 1.000 
rs11030918 0.543 1.000 0.294 0.996 0.785 1.000 0.301 0.996 
rs12806698 0.517 1.000 1.000 1.000 0.517 1.000 1.000 1.000 
rs1042927 0.800 1.000 0.706 1.000 0.723 1.000 0.717 1.000 
 
TK2 
 
rs3743712 0.970 1.000 0.764 1.000 0.631 1.000 0.493 1.000 
rs11859474 0.677 1.000 0.302 0.997 0.905 1.000 0.241 0.985 
rs2288399 0.911 1.000 0.734 1.000 0.984 1.000 0.730 1.000 
 
SAMHD1 
rs8124728 0.739 1.000 0.017 0.495 0.661 1.000 0.015 0.350 
rs1291142 0.455 1.000 0.718 1.000 0.237 0.999 0.562 1.000 
rs1891643 0.672 1.000 0.619 0.698 0.862 1.000 0.027 0.619 
SLC19A1 rs1051266 0.079 0.858 1.000 0.984 0.067 0.806 0.482 1.000 
(Red Bold) p<0.05 Significant association with sensory neuropathy.  
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3.5.3 Analysis of associations between haplotypes and SN. 
Haplotype analysis was performed for all the genes with more than one SNP, using the 
sliding window approach in PLINK. Two and three-SNP haplotype combinations were 
analysed.  The haplotype analysis for multivariate was performed correcting for age and 
height.  
 
In univariate analysis, no haplotype was associated with SN (Table 3.10). One haplotype 
was associated with SN in the multivariate analysis (Table 3.10). This was the three-SNP 
(rs8124728|rs1291142|rs1891643) haplotype combination “GGA” of the SAMHD1 gene, 
which was found to be significant in the multivariate analysis, (PEMP1, p=0.021). 
However, this haplotype was not significantly associated with SN after correction for 
multiple testing (PEMP1>0.05; Table 3.10).  
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Table 3.10 The univariate and multivariate analysis of associations between haplotypes and sensory neuropathy. 
Significant p values<0.05 shown in red. 
Gene Haplo- 
type 
SNPs in the haplotype Frequency 
SN+ Cases 
N=143 
Frequency 
SN- 
Controls 
N=120 
Univariate 
analysis 
Multivariate 
analysis 
PEMP1 PEMP2 PEMP1 PEMP2 
MTHFR GA rs1801131|rs1801133 0.001 0.012 0.565 1.000 0.575 1.000 
 TA rs1801131|rs1801133 0.061 0.057 0.802 1.000 0.919 1.000 
 GG rs1801131|rs1801133 0.117 0.153 0.227 1.000 0.141 1.000 
 TG rs1801131|rs1801133 0.812 0.778 0.342 1.000 0.227 1.000 
ABCG2 TAC rs12505410|rs2725252|rs3114018 0.105 0.097 0.759 1.000 0.517 1.000 
 GCC rs12505410|rs2725252|rs3114018 0.110 0.084 0.295 1.000 0.273 1.000 
 TCC rs12505410|rs2725252|rs3114018 0.223 0.215 0.824 1.000 0.993 1.000 
 TAA rs12505410|rs2725252|rs3114018 0.085 0.100 0.512 1.000 0.617 1.000 
 GCA rs12505410|rs2725252|rs3114018 0.031 0.016 0.231 1.000 0.327 1.000 
 TCA rs12505410|rs2725252|rs3114018 0.445 0.488 0.284 1.000 0.248 1.000 
 CCT rs2725252|rs3114018|rs2622604 0.024 0.020 0.697 1.000 0.592 1.000 
 CAT rs2725252|rs3114018|rs2622604 0.113 0.095 0.466 1.000 0.412 1.000 
 ACC rs2725252|rs3114018|rs2622604 0.099 0.091 0.746 1.000 0.487 1.000 
 CCC rs2725252|rs3114018|rs2622604 0.314 0.280 0.362 1.000 0.521 1.000 
 AAC rs2725252|rs3114018|rs2622604 0.088 0.101 0.579 1.000 0.611 1.000 
 CAC rs2725252|rs3114018|rs2622604 0.362 0.414 0.196 1.000 0.146 1.000 
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Table 3.10 continued. The univariate and multivariate analysis of associations between haplotypes and sensory 
neuropathy. Significant p values<0.05 shown in red. 
Gene Haplo- 
type 
SNPs in the haplotype Frequency 
SN+ Cases 
N=143 
Frequency SN- 
Controls 
N=120 
Univariate analysis Multivariate analysis 
PEMP1 PEMP2 PEMP1 PEMP2 
SLC28A3 GC rs7853758|rs4877847 0.295 0.294 0.974 1.000 0.768 1.000 
 AA rs7853758|rs4877847 0.340 0.303 0.377 1.000 0.192 0.999 
 GA rs7853758|rs4877847 0.198 0.220 0.501 1.000 0.532 1.000 
RRM1 ACA rs1465952|rs11030918|rs12806698 0.022 0.019 0.995 1.000 0.516 1.000 
 ACC rs1465952|rs11030918|rs12806698 0.193 0.165 0.430 1.000 0.653 1.000 
 ATC rs1465952|rs11030918|rs12806698 0.260 0.298 0.354 1.000 0.630 1.000 
 GTC rs1465952|rs11030918|rs12806698 0.525 0.518 0.920 1.000 0.929 1.000 
 CCC rs11030918|rs12806698|rs1042927 0.041 0.041 0.974 1.000 0.754 1.000 
 TCC rs11030918|rs12806698|rs1042927 0.131 0.143 0.682 1.000 0.867 1.000 
 CAA rs11030918|rs12806698|rs1042927 0.018 0.013 0.607 1.000 0.524 1.000 
 CCA rs11030918|rs12806698|rs1042927 0.151 0.125 0.366 1.000 0.536 1.000 
 TCA rs11030918|rs12806698|rs1042927 0.658 0.679 0.627 1.000 0.665 1.000 
SLC28A1 GCA rs2290272|rs8187758Â |rs2242046 0.021 0.002 0.090 0.996 0.1 0.997 
 AAG rs2290272|rs8187758Â |rs2242046 0.126 0.183 0.082 0.943 0.204 1.000 
 ACG rs2290272|rs8187758Â |rs2242046 0.080 0.079 0.964 1.000 0.950 1.000 
 GCG rs2290272|rs8187758Â |rs2242046 0.773 0.737 0.455 1.000 0.640 1.000 
TK2 GGG rs3743712|rs11859474|rs2288399 0.104 0.119 0.603 1.000 0.808 1.000 
 AGG rs3743712|rs11859474|rs2288399 0.046 0.037 0.752 1.000 0.867 1.000 
 GAA rs3743712|rs11859474|rs2288399 0.261 0.266 0.882 1.000 0.680 1.000 
 GGA rs3743712|rs11859474|rs2288399 0.012 0.024 0.348 1.000 0.416 1.000 
 AGA rs3743712|rs11859474|rs2288399 0.578 0.554 0.607 1.000 0.959 1.000 
SAMHD1 GGG rs8124728|rs1291142|rs1891643 0.187 0.188 0.978 1.000 0.670 1.000 
 GGA rs8124728|rs1291142|rs1891643 0.030 0.064 0.066 0.907 0.021 0.566 
 AAA rs8124728|rs1291142|rs1891643 0.175 0.163 0.684 1.000 0.755 1.000 
 GAA rs8124728|rs1291142|rs1891643 0.608 0.586 0.592 1.000 0.394 1.000 
 91 
 
3.6 Association between mtDNA copy number and sensory neuropathy  
3.6.1 Primer optimization using regular PCR 
 
Two   sets of PCR primers for the GAPDH gene and the two sets of PCR primers for 
the mt-ND1 gene were optimized initially using the gradient PCR to determine the 
optimal annealing temperature before using them in the qPCR. Both sets of GAPDH 
and mt-ND1 primer pairs worked at all temperatures included in the gradient (see 
Figure 3.9 for GAPDH primer pairs and Figure 3.10 for mt-ND1 primer pairs) and 
therefore were tested in the qPCR assay. 
 
 
 
Figure 3.9: Agarose gel 1% (w/v) electrophoresis images of the PCR products for GAPDH primer 
pairs.  
a) GAPDH primer pair 2 at temperature gradient between 45°C and 50°C (lanes 2-9). Clear NTC lane 
indicated no contamination. Expected product size was 197 bp.  
b) GAPDH primer pair 1 at temperature gradient between 48°C and 53°C (lanes 2-9). Clear NTC lane 
indicated no contamination. Expected product size was 208 bp. Kapa DNA Ladder with the following 
sizes 100+200+400+800+1600+4000+8000 bp was used and the last lane was a no template control 
(NTC).   
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The mt-ND1 primer pairs were also demonstrated to be specific with all the selected 
PCR gradient temperatures. 
Both the primer pairs were tested in the qPCR assay. 
 
 
          
 
Figure 3.10: Agarose gel 1% (w/v) electrophoresis images of the PCR products for mt-ND1 
primer pairs.  
a) mt-ND1 primer pair 1 at temperature gradient between 47°C and 54°C from (lanes 2-9). 
Expected product size was 243 bp.  
b) mt-ND1 primer pair 2 at gradient temperature used was between 58°C and 62 °C from (lanes 
2-4). Expected product size was 154 bp.  
Kapa DNA Ladder with the following sizes 100+200+400+800+1600+4000+8000 bp was used and 
the last lane was a no template control (NTC).   
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3.6.2 qPCR optimization 
3.6.2.1 Standard curves 
 
In order to calculate the PCR efficiency of each primer pair, a   four point series of 
tenfold dilutions of the HEK293 DNA was used.   
The four DNA dilutions were used to amplify the target gene mt-ND1 and the reference 
gene GAPDH using duplicate reactions.  Post the real-time PCR the CT values were 
used to construct a standard curve using the second derivative analysis method on 
the Roche Light cycler 480 software.  
 
 
Figure 3.11 Standard curve graph used to determine the PCR efficiencies of GAPDH primers. 
 
 
Figure 3.12 Standard curve graph used to determine the PCR efficiencies of mt-DN1 primers. 
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The DNA amount, primer concentrations and annealing temperatures were altered in 
order to attain similar amplification efficiencies for the target and the reference gene.  
The PCR efficiencies were calculated from standard curve slopes using the Life Cycler 
software. The determination of the corresponding real-time PCR efficiency (E) of one 
cycle in the exponential phase was calculated using the equation: E=10[-1/slope] (and 
the PCR efficiencies for all the four primer pairs used were within the range between 
90 % and 105 % (Table 3.11.). 
 
Table 3.11 qPCR PCR efficiencies for the primers selected for optimization.  
 REFERENCE GENE  TARGET GENE 
Primer name GAPDH1 GAPDH2 mt-ND1A mt-ND1B 
Slope -3.477 -3.229 -3.550 -3.230 
Efficiency (%) 93.9 104 91.3 104 
Y-Intercept 25.79 26.04 24.21 20.68 
Ta (°C) 50 °C 50 °C 50 °C 58 °C 
Error  0.026 0.002 0.056 0.131 
 
3.6.2.2 Melting curves  
 
The post-amplification melting analysis was performed in order to check the specificity 
of the primers. Following the post amplification melting curve analysis for the GAPDH 
primer pair 1 (Figure 3.13) one peak was observed showing that it was specific to the 
region of interest, whereas primer pair 2 (Figure 3.14) showed two peaks on its melting 
curve for the gradient temperature range tested indicating non-specificity. Hence for 
the reference gene GAPDH primer pair 1 was chosen as the primer pair to be used in 
the mtDNA copy number quantification assay. For the target gene both the primer 
pairs for the mt-ND1 gene have shown to be specific with no secondary peaks 
observed on the melting curve, both the primer pairs for the mt-ND1 target gene were 
both eligible for selection, as a result primer pair 2 (Figure 3.15) was chosen to be 
used in the assay for mtDNA copy number quantification assay.  
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Figure 3.13 A melting curve analysis test for GAPDH primer Pair 1. 
Figure 3.14 A melting curve analysis test for GAPDH primer pair 2. 
 
Figure 3.15 A melting curve analysis test for mt-ND1 primer pair 2. 
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3.6.2.3. Validation of qPCR assay for mtDNA copy number calculation 
 
A validation procedure for the mtDNA copy number quantification assay was used to 
confirm the accuracy and reproducibility of the qPCR assay before the cohort samples 
were tested. HEK293 cells were treated with EtBr for 6 days and DNA was extracted 
from cells preserved at the day 0 (pre-treatment), days 3 and 6 time points. DNA 
concentrations were 163.3 ng/µl and for the following days, day 3 and 6 post-treatment 
with EB were 236.9 ng/µl and 94.2 ng/µl respectively. The DNA was diluted to a 
working concentration of 20 ng/µl.  
 
The DNA from day 0(untreated) , day 3 (treated with EtBr) and  day 6 (treated with 
EtBr) were amplified using the GAPDH primer pair 1 and mt-ND1 primer pair 2; this 
was carried out in triplicates and the Cts were averaged and compared for statistical 
differences between the days. To calculate the assay precision the Pfaffl equation for 
fold change calculations was used to measure the inter-treatment change of the Cts 
between the control group (pre-treatment) and the treated groups (day 3 and 6).  
Averages of Ct values for replicate samples were calculated as shown in Table 3.12. 
The Cts values of the target gene increased from day 0 to day 3, and from day 3 to 
day 6, indicating decreased mtDNA, and the Ct values of the reference gene remained 
fairly constant for all time points. 
 
Table 3.12: qPCR threshold cycle (Ct) values obtained using the DNA of HEK293 
cells at three time points.  
Days Target (mt-ND1) Reference (GAPDH) 
replicate Ct 
Values 
Average 
Ct 
replicate  Ct 
Values 
Average Ct 
0 14.28 16.00 15.14 23.08 23.51 23.3 
3 16.82 17.52 17.17 22.89 22.58 22.7 
6 19.17 19.87 19.52 22.91 22.87 22.9 
 
Table 3.13 shows the fold changes from day 0 to day 6. The Livak equation (2-ΔΔCT) 
was used for calculation of fold change of nDNA: mtDNA ratio between EtBr treated 
and untreated HEK293 cells.   
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The mtDNA to nDNA ratio varied across the respective days. The EtBr was effective 
in inducing mtDNA copy number depletion in HEK293 cells. Day 3 showed a 6-fold 
decrease in mt-ND1 gene compared to day 0, while on day 6 the fold change increased 
to 27.67-fold compared to day 0.  
These results supported the expected decrease over time in mtDNA in cells treated 
with EtBr and proved that the qPCR assay was working correctly to detect mtDNA 
change.  
Table 3.13: The fold change ratios of mt-ND1 relative to GAPDH in HEK293 cells. 
 
 Days ΔΔCt 2-ΔΔCt (fold change) 
(Treated compared to 
untreated) 
(0-3) 2.59 6.02 
(3-6) 2.195 4.57 
(0-6) 4.79 27.67 
 
3.6.3 Associations between mtDNA copy number and sensory neuropathy. 
 
We performed the mtDNA: nDNA qPCR assay in 263 samples in duplicate wells. After 
QC, 27 samples were excluded and 236 samples remained for further analysis leaving 
130 cases and 106 controls. mtDNA copy number was compared between HIV 
patients with SN and those without SN using the ΔΔCt method (Table 3.14).  
Table 3.14 Fold change calculations for the cases and controls. 
The Man-Whitney U-test was used to compare differences in the mean mtDNA ratios 
of the cases and controls peripheral blood mononuclear cells (PBMCs) (1.445 vs. 
1.268) (p=0.159; Figure 3.16).    
Subjects Mean Cts 
GAPDH 
Mean Cts  
mt-ND1 
ΔCt ΔΔCt 2-ΔΔCt  
(fold change) 
Cases (with SN) 21.022 13.814 7.208 -0.184 1.136 
Controls (without SN) 21.132 13.740 7.392 
 98 
 
S
N
S
N
-f
re
e
0
2
4
6
8
m tD N A \n D N A  ra tio s  S N  v s . N o  S N
m
tD
N
A
/n
D
N
A
 r
a
ti
o
s p  =  0 .1 5 9
 
Figure 3.16 the comparison of mtDNA\nDNA Ct ratios between SN and without SN samples, using the 
non-parametric Man-Whitney test. 
 
 
 
 
3.7 Associations between SNPs and mtDNA copy number 
 
A total of 26 SNPs were examined for association with mtDNA copy number both in a 
univariate and multivariate analysis method. The mtDNA copy number phenotype was 
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expressed as Ct ratios between mt-ND1 (mtDNA) and GAPDH (nDNA) 
(mtDNA/nDNA) and as a result the phenotype was analysed for association with the 
SNPs as a continuous or quantitative trait using PLINK. 
3.7.1 Univariate analysis for association with mtDNA copy number 
 
The single SNP univariate analyses for association with mtDNA copy number 
(mtDNA/nDNA ratio) was done using PLINK deploying four association tests, the 
allelic test and three genotype tests (dominant, recessive and co-dominant/genotypic). 
All 26 SNPs used in the univariate analysis of association with mtDNA copy number 
did not attain the threshold significance level for the point-wise estimates (PEMP1) 
and remained non-significant after correction for multiple testing (PEMP2) in all four 
models tested (allelic, genotypic, dominant and recessive) (see Table 3.15).  
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Table 3.15 Univariate analyses for association with mtDNA copy number. 
Univariate analyses for association with mtDNA copy number. 
Gene SNP Allelic Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
Drug transporter genes 
ABCC5 rs3749442 0.445 1.000 0.448             1.000 0.447             1.000 0.446             1.000 
 
ABCG2 
rs12505410 0.277 1.000 0.276        1.000 0.279        1.000 0.280        1.000 
rs2725252 0.897 1.000 0.897             1.000 0.896             1.000 0.897             1.000 
rs3114018 0.323 1.000 0.322           1.000 0.322        1.000 0.320        1.000 
rs2622604 0.305 1.000 0.306        1.000 0.305            1.000 0.304        1.000 
SLC28A3 rs7853758 0.281 0.999 0.277        0.999 0.281        0.999 0.277        0.999 
rs4877847 0.220 0.996 0.218         0.996 0.219        0.996 0.220        0.996 
 
SLC28A1 
rs2290272 0.163 0.982 0.161         0.982 0.160        0.982 0.161        0.981 
rs8187758 0.313 1.000 0.313        1.000 0.313        1.000 0.313        1.000 
rs2242046 0.813 1.000 0.811             1.000 0.810             1.000 0.809             1.000 
dNTP pool regulator genes 
MTHFR rs1801131 0.619 1.000 0.625 1.000 0.621 1.000 0.622 1.000 
MTHFR rs1801133 0.522 1.000 0.522 1.000 0.525 1.000 0.524 1.000 
RRM2 rs7574663 0.989 1.000 0.988 1.000 0.988 1.000 0.988 1.000 
DHFR rs1650723 0.349 1.000 0.349 1.000 0.352 1.000 0.345 1.000 
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Table 3.15 continued. Univariate analyses for association with mtDNA copy number. 
Gene SNP Allelic Genotypic Dominant Recessive 
 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
dNTP pool regulator genes 
RRM2B rs16918482 0.332             1.000 0.333             1.000 0.334             1.000 0.331             1.000 
 
RRM1 
rs1465952 0.583             1.000 0.58             1.000 0.58             1.000 0.580             1.000 
rs11030918 0.458             1.000 0.453             1.000 0.454             1.000 0.457             1.000 
rs12806698   0.964             1.000 0.963             1.000 0.964             1.000 0.963             1.000 
rs1042927 0.346        1.000 0.344        1.000 0.345        1.000 0.346        1.000 
 
TK2 
rs3743712 0.592             1.000 0.590             1.000 0.588             1.000 0.593             1.000 
rs11859474 0.673             1.000 0.671             1.000 0.671             1.000 0.673             1.000 
rs2288399 0.913             1.000 0.912             1.000 0.912             1.000 0.912             1.000 
 
SAMHD1 
 
rs8124728 0.629             1.000 0.632             1.000 0.632             1.000 0.629             1.000 
rs1291142 0.757             1.000 0.760             1.000 0.758             1.000 0.758             1.000 
rs1891643 0.659             1.000 0.661             1.000 0.662             1.000 0.659             1.000 
SLC19A1 rs1051266 0.661             1.000 0.661             1.000 0.662             1.000 0.661             1.000 
    (Red) p<0.05 Significant association with mtDNA copy number.
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3.8 SNP association with the CD4+ T cell count  
 
A total of 26 SNPs were examined for association with CD4+ T cell count performed 
using PLINK for univariate and multivariate methods. The analysis used four models 
for testing; the allelic and three genotype tests (dominant, genotypic, and recessive). 
CD4+ T cell count data were available for only one-time point post-ART initiation and 
was not the same time point for all participants. 
3.8.1 Univariate analysis of association between SNPs and CD4+ T cell count  
 
Five SNPs were associated with CD4+ T cell count in the univariate analysis before 
correction for multiple testing (Table 3.16, highlighted). These included: 
 
ABCG2 rs2725252: This is an intron variant, and it was found to be significantly 
associated with CD4+ T cell count in this HIV-infected SA cohort on d4T-ART, for all 
the four test models (allelic, genotypic, dominant and recessive; PEMP1 =  0.005, p = 
0.005, p = 0.004, p = 0.005, respectively).   
 
SLC28A3 rs4877847: The intron variant was found to be significantly associated with 
CD4+ T cell count in this HIV-infected SA cohort on d4T-ART, for all the four test 
models (allelic, genotypic, dominant and recessive; PEMP1 = 0.025, p = 0.026, p = 
0.026, p = 0.026 respectively). 
 
SLC28A1 SNPs rs2290272 and rs8187758: These missense variants of the 
SLC28A1 d4T transporter gene were found to be significantly associated with CD4 
count in this HIV-infected SA cohort on d4T-ART.The association of the rs2290272 
polymorphism with CD4+ T cell count occurred in all the four models tested, for the 
point-wise (PEMP1) p-values (allelic, genotypic, dominant and recessive; p=0.003,  
p = 0.003, p = 0.003, p = 0.003 respectively).  
 
The association of the SLC28A1 rs8187758 polymorphism with CD4+ T cell count 
showed significant  association for both the point-wise estimates and the family wise 
correction in all four models tested : PEMP1; p = 0.00163, p = 0.00174, p = 0.00147, 
p = 0.00163.   
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TK2 rs2288399: The thymidine kinase gene (TK2), dNTP pool regulator gene intron 
variant was found to be significantly associated with CD4+ T cell count in this HIV-
infected SA cohort on d4T-ARTin all the four models tested for the point wise (PEMP1) 
p-values (allelic, genotypic, dominant and recessive; p=0.027, p=0.027, p=0.028, 
p=0.027 respectively). 
 
After correction for multiple testing, only the SLC28A1 rs8187758 remained 
significantly associated with CD4+ T cell count, with PEMP2 values of 0.042 or 0.043 
for all four models (Table 3.16). 
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Table 3.16 The univariate analysis of associations between SNPs and CD4+ T cell count. 
 
Gene    SNP Allelic  Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
Drug transporter genes 
ABCC5 rs3749442 0.736 1.000 0.738 1.000 0.736 1.000 0.740 1.000 
 
ABCG2 
rs12505410 0.173 0.999 0.172 0.989 0.175 0.990 0.173 0.990 
rs2725252 0.005 0.107 0.005 0.105 0.004 0.109 0.005 0.106 
rs3114018 0.728 1.000 0.728 1.000 0.728 1.000 0.728 1.000 
rs2622604 0.068 0.815 0.067 0.815 0.069 0.813 0.067 0.814 
SLC28A3 rs7853758 0.966 1.000 0.967 1.000 0.966 1.000 0.967 1.000 
rs4877847 0.025 0.475 0.026 0.472 0.026 0.472 0.026 0.473 
 
SLC28A1 
rs2290272 0.003 0.080 0.003 0.078 0.003 0.081 0.003 0.079 
rs8187758 0.00163 0.04256 0.00174 0.0418 0.00147 0.04252 0.002 0.04295 
rs2242046 0.250 0.999 0.253 0.999 0.249 0.999 0.253 0.999 
dNTP pool regulator genes 
 
MTHFR 
rs1801131 0.824 1.000 0.8245 1.000 0.823 1.000 0.828 1.000 
rs1801133 0.979 1.000 0.979 1.000 0.979 1.000 0.978 1.000 
RRM2 rs7574663 0.271 1.000 0.271 0.999 0.268      1.00 0.266     1.000 
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Table 3.16 continued. The univariate analysis of associations between SNPs and CD4+ T cell count. 
 
Gene    SNP Allelic  Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
dNTP pool regulator genes 
DHFR rs1650723 0.099 0.920 0.097 0.918 0.097 0.918 0.099 0.918 
RRM2B rs16918482 0.454 1.000 0.4507 1.000 0.452 1.000 0.448 1.000 
 
RRM1 
rs1465952 0.755 1.000 0.755 1.000 0.754 1.000 0.758 1.000 
rs11030918 0.516 1.000 0.520 1.000 0.521 1.000 0.517 1.000 
rs12806698 0.574 1.000 0.572 1.000 0.574 1.000 0.573 1.000 
rs1042927 0.095 0.908 0.093 0.905 0.093 0.905 0.092 0.905 
 
TK2 
 
rs3743712 0.647 1.000 0.646 1.000 0.651 1.000 0.646 1.000 
rs11859474 0.835 1.000 0.836 1.000 0.839 1.000 0.836 1.000 
rs2288399 0.027 0.484 0.027 0.482 0.028 0.481 0.027 0.483 
 
SAMHD1 
rs8124728 0.124 0.958 0.123 0.958 0.124 0.957 0.125 0.957 
rs1291142 0.694 1.000 0.695 1.000 0.695 1.000 0.692 1.000 
rs1891643 0.847 1.000 0.847 1.000 0.848 1.000 0.846 1.000 
SLC19A1 rs1051266 0.660 1.000 0.658 1.000 0.659 1.000 0.661 1.000 
    (Red) p<0.05 Significant association with CD4 count restitution. 
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3.8.2 Multivariate linear regression analysis of associations between SNPs and 
CD4+ T cell count  
 
The multivariate linear regression analysis of associations between SNPs and CD4+ 
T cell count, corrected for one clinical variable (number of months HIV+). This analysis 
was performed using PLINK deploying four association tests:  the allelic test and three 
genotype tests (dominant, recessive and co-dominant/genotypic). Four of the loci that 
were identified as significantly associated with CD4+ T cell count in the univariate 
analysis (ABCG2 rs2725252, SLC28A3 rs4877847, SLC28A1 rs2290272 and 
rs8187758), remained significantly associated with CD4+ T cell count in the 
multivariate analysis, as discussed below and Table 3.17.However none of the SNPs 
remained significant in multivariate analyses after correction for multiple testing 
(PEMP2>0.05). 
 
ABCG2 rs2725252: This polymorphism of the ABCG2 gene was found to be 
significantly associated with CD4+ T cell count recovery after correcting for the number 
of months HIV+ in all the tests for the point-wise estimates (PEMP1) the allelic, 
genotypic, dominant and recessive, p=0.019, p=0.011, p=0.078, p=0.015 respectively 
and not significantly associated with CD4 count in the family-wise correction (PEMP2) 
in all the four tests performed.  
 
SLC28A3 rs4877847: this polymorphism of the SLC28A3 was also found to be 
significantly associated with CD4+ T cell count (current) after correcting for the number 
of months HIV+, in three tests for the point-wise estimates (PEMP1) the allelic and 
genotypic, p=0.023 and p=0.024; the rs4877847 polymorphism was not significantly 
associated with CD4 count in PEMP2 in all the four tests performed.  
 
SLC28A1 rs2290272 : this polymorphism of the SLC28A1 gene was also found to be 
significantly associated with CD4 count after correcting for the number of months 
HIV+, in all the four tests allelic, genotypic and dominant, for the point-wise estimates 
(PEMP1), p=0.01, p=0.039 and p=0.028 respectively, but not significantly associated 
with CD4 count in PEMP2.  
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SLC28A1 rs8187758 : a polymorphism of the SLC28A1 gene was also found to found 
to be significantly associated with CD4 count after correcting for the number of months 
HIV+, in two tests for PEMP1 allelic and dominant, p=0.002 and p=0.029 respectively, 
the PEMP2 values were not significantly associated with CD4 count. This observation 
is different with the univariate analysis in that in the univariate analysis all the PEMP1 
and PEMP2 for all the models tested were significantly associated with CD4 Count 
whereas with the multivariate analysis, only the allelic and the dominant tests were 
significantly associated with CD4 count in the point-wise estimates (PEMP1) but not 
significant in the family-wise correction (PEMP2). 
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Table 3.17 The Multivariate analysis of associations between SNPs and CD4+ T cell count. 
  
Gene    SNP Allelic  Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
Drug transporter genes 
ABCC5 rs3749442 0.962 1.000 0.937 1.000 0.922 1.000 0.922 1.000 
 
 
ABCG2 
rs12505410 0.275 1.000 0.182 0.987 0.398 1.000 0.195 0.991 
rs2725252 0.019 0.381 0.012 0.223 0.078 0.858 0.015 0.305 
rs3114018 0.681 1.000 0.414 1.000 0.613 1.000 0.161 0.975 
rs2622604 0.164 0.987 0.428 1.000 0.185 0.993 0.485 1.000 
SLC28A3 rs7853758 0.978 1.000 0.991 1.000 0.240 0.999 0.224 0.996 
rs4877847 0.023 0.441 0.024 0.426 0.056 0.756 0.072 0.795 
 
SLC28A1 
rs2290272 0.012 0.263 0.039 0.574 0.028 0.497  0.077 0.821 
rs8187758 0.016 0.327 0.094 0.882 0.027 0.479 0.151 0.970 
rs2242046 0.232 0.998 1.000 1.000 0.233 0.998 1.000 1.000 
dNTP pool regulator genes 
MTHFR rs1801131 0.965   1.000 0.787 1.000 0.971 1.000 0.778    1.000 
rs1801133 0.796 1.000 0.677 1.000 0.854 1.000 0.678 1.000 
RRM2 rs7574663 0.380 1.000 0.291 0.999 0.493 1.000 0.296 1.000 
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Table 3.17 continued. The Multivariate analysis of associations between SNPs and CD4+ T cell count. 
 
Gene    SNP Allelic  Genotypic Dominant Recessive 
PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 PEMP1 PEMP2 
dNTP pool regulator genes 
RRM2B rs16918482 0.265 0.100 0.449 1.000 0.309 1.000 0.465 1.000 
 
 
RRM1 
rs1465952 0.748 1.000 0.721 1.000 0.943 1.000 0.530 1.000 
rs11030918 0.575 1.000 0.572 1.000 0.658 1.000 0.599 1.000 
rs12806698 0.245 0.998 1.000 1.000 0.246 0.999 1.000 1.000 
rs1042927 0.178 0.991 0.064 0.780 0.313 1.000 0.073 0.821 
 
TK2 
rs3743712 0.628 1.000 0.469 1.000 0.941 1.000 0.314 1.000 
rs11859474 0.988 1.000 0.886 1.000 0.9 1.000 0.849 1.000 
rs2288399 0.106 0.934 0.074 0.812 0.224 0.998 0.087 0.859 
 
SAMHD1 
rs8124728 0.077 0.860 0.323 1.000 0.085 0.879 0.412 1.000 
rs1291142 0.738 1.000 0.760 1.000 0.550 1.000 0.658 1.000 
rs1891643 0.853 1.000 0.946 1.000 0.843 1.000 0.964 1.000 
SLC19A1 rs1051266 0.751 1.000 0.491 1.000 0.298  1.000 0.259 0.998 
       (Red) p<0.05 Significant association with CD4 count. 
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3.8.3 Analysis of associations between haplotypes and CD4+ T cell count. 
 
Haplotype analysis was performed for all the genes with more than one SNP, using 
the sliding window approach in PLINK. The associations between haplotypes  and  
CD4+ T cell  count was examined in both a univariate approach, and  using a 
multivariate linear regression approach which corrected for the number of months 
HIV+. Seven haplotypes in three genes were found to be associated with CD4+ T cell 
count recovery in uinivariate and multivariate analyses with PEMP1<0.05 before 
correction for multiple testing, One haplotype in ABCG2 remained significantly 
associated with CD4+ T cell count in univariate analysis after correction for multiple 
testing with PEMP2<0.05, but did not survive correction for multiple testing in the 
multivariate testing (Table 3.18).   
 
ABCG2: A three SNP (rs12505410|rs2725252|rs3114018) Haplotype “TAC” of the 
ABCG2 gene was found to be associated with CD4 count recovery on the univariate 
analysis for PEMP1 and PEMP2, p=0.001 and p=0.042 respectively. In the 
multivariate analysis this haplotype was also found to be significantly associated with 
CD4+ T cell count, PEMP1 = 0.004.  
 
The three-SNP (rs2725252|rs3114018|rs2622604) haplotype combinations “CAT”, 
“ACC” and “CAC” of the ABCG2 gene were found to be significantly associated with 
CD4+ T cell count recovery in the univariate analysis with PEMP1, at p=0.009, 
p=0.002 and p=0.009 respectively and  in multivariate analysis PEMP1, at, p=0.031, 
p=0.007 and p=0.027 respectively. 
 
SLC28A3: A two-SNP (rs7853758|rs4877847) haplotype combination “AC” of the 
SLC28A3 gene was found to associated with CD4 count recovery on the univariate 
and multivariate analysis, for the PEMP1, p=0.033 and p=0.016 respectively. 
 
SLC28A1:The three-SNP haplotype combinations “AAG” and “GCG” of the SLC28A1 
gene (rs2290272|rs8187758Â |rs2242046) were found to be associated with CD4 
count recovery in the univariate and multivariate analysis for PEMP1, (“AAG” p=0.003 
and p=0.002 respectively) and (“GCG” p=0.002 and p=0.008 respectively).  
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Table 3.18 Univariate and multivariate analysis of associations between 
haplotypes and CD4+ T cell count. Significant p values<0.05 shown in red. 
 
 
 
 
 
Gene Haplotype SNPs in the haplotype Univariate 
analysis 
Multivariate 
analysis 
PEMP1 PEMP2 PEMP1 PEMP2 
MTHFR GA rs1801131|rs1801133 0.39 1.000 0.275 1.000 
 TA rs1801131|rs1801133 0.744 1.000 0.234 1.000 
 GG rs1801131|rs1801133 0.978 1.000 0.988 1.000 
 TG rs1801131|rs1801133 0.996 1.000 0.407 1.000 
ABCG2 TAC rs12505410|rs2725252|rs3114018 0.001 0.042 0.004 0.156 
 GCC rs12505410|rs2725252|rs3114018 0.148 0.997 0.219 1.000 
 TCC rs12505410|rs2725252|rs3114018 0.335 1.000 0.483 1.000 
 TAA rs12505410|rs2725252|rs3114018 0.475 1.000 0.697 1.000 
 GCA rs12505410|rs2725252|rs3114018 0.805 1.000 0.962 1.000 
 TCA rs12505410|rs2725252|rs3114018 0.490 1.000 0.511 1.000 
 CCT rs2725252|rs3114018|rs2622604 0.098 0.980 0.076 0.953 
 CAT rs2725252|rs3114018|rs2622604 0.009 0.299 0.031 0.700 
 ACC rs2725252|rs3114018|rs2622604 0.002 0.070 0.007 0.25 
 CCC rs2725252|rs3114018|rs2622604 0.168 0.999 0.346 1.000 
 AAC rs2725252|rs3114018|rs2622604 0.372 1.000 0.542 1.000 
 CAC rs2725252|rs3114018|rs2622604 0.009 0.321 0.027 0.653 
SLC28A3 AC rs7853758|rs4877847 0.033 0.725 0.016 0.487 
 GC rs7853758|rs4877847 0.356 1.000 0.459 1.000 
 AA rs7853758|rs4877847 0.117 0.990 0.065 0.922 
 GA rs7853758|rs4877847 0.282 1.000 0.427 1.000 
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Table 3.18 continued. Univariate and multivariate analysis of associations 
between haplotypes and CD4+ T cell count. Significant p values <0.05 shown in 
red. 
(Red) p<0.05 Significant association with CD4 count restitution. 
 
Gene Haplotype SNPs in the haplotype Univariate 
analysis 
Multivariate 
analysis 
PEMP1 PEMP2 PEMP1 PEMP2 
 ACC rs1465952|rs11030918|rs12806698 0.653 1.000 0.875 1.000 
 ATC rs1465952|rs11030918|rs12806698 0.793 1.000 0.855 1.000 
 GTC rs1465952|rs11030918|rs12806698 0.790 1.000 0.777 1.000 
 CCC rs11030918|rs12806698|rs1042927 0.320 1.000 0.473 1.000 
 TCC rs11030918|rs12806698|rs1042927 0.121 0.992 0.149 0.997 
 CAA rs11030918|rs12806698|rs1042927 0.571 1.000 0.381 1.000 
 CCA rs11030918|rs12806698|rs1042927 0.305 1.000 0.594 1.000 
 TCA rs11030918|rs12806698|rs1042927 0.644 1.000 0.642 1.000 
SLC28A1 GCA rs2290272|rs8187758Â |rs2242046 0.334 1.000 0.335 1.000 
 AAG rs2290272|rs8187758Â |rs2242046 0.003 0.126 0.025 0.632 
 ACG rs2290272|rs8187758Â |rs2242046 0.816 1.000 0.610 1.000 
 GCG rs2290272|rs8187758Â |rs2242046 0.002 0.082 0.008 0.280 
TK2 GGG rs3743712|rs11859474|rs2288399 0.128 0.994 0.275 1.000 
 AGG rs3743712|rs11859474|rs2288399 0.104 0.984 0.234 1.000 
 GAA rs3743712|rs11859474|rs2288399 0.839 1.000 0.988 1.000 
 GGA rs3743712|rs11859474|rs2288399 0.220 1.000 0.407 1.000 
 AGA rs3743712|rs11859474|rs2288399 0.253 1.000 0.326 1.000 
SAMHD1 GGG rs8124728|rs1291142|rs1891643 0.847 1.000 0.850 1.000 
 GGA rs8124728|rs1291142|rs1891643 0.596 1.000 0.664 1.000 
 AAA rs8124728|rs1291142|rs1891643 0.123 0.993 0.077 0.953 
 GAA rs8124728|rs1291142|rs1891643 0.418 1.000 0.306 1.000 
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CHAPTER 4: DISCUSSION  
 
Antiretroviral therapy (ART) including NRTIs has changed HIV from a chronic disease 
to a manageable disease by curbing the death rate and the state of illness 
encountered by HIV+ patients (Margolis et al., 2014). However the use of ART is 
associated with a wide range of toxic effects such as peripheral neuropathy, 
lipodystrophy and pancreatitis (Kallianpur and Hulgan, 2009). Not all patients who are 
exposed to NRTIs develop mitochondrial toxicity such as sensory neuropathy. This 
suggests that factors such as underlying genetic variation can influence the 
development of SN in response to NRTI use.  
 
Pharmacogenetics refers to the study of altered drug response as a result of genetic 
changes (Kalow, 2002; Johnson, 2003) and this may help to predict who suffers off-
target side-effects of ART and who does not. In particular, human genetic variation 
could influence SN development via the so-called ADME genes which control drug 
absorption, distribution, metabolism and excretion / elimination (Kerb et al., 
2009). These can be core determinant of the toxicities and efficacies of ARVs 
(Johnson, 2003; Michaud et al. 2012).  In addition, many of the same ADME genes 
also control the relative levels of the natural dNTP pool with which the NRTIs compete 
inside cells.  Variation in endogenous dNTP or RN levels could be a key second 
mechanism by NRTI toxicity could occur (Selvaraj et al., 2014). 
 
In the current study single nucleotide polymorphisms in genes encoding d4T-
transporters and enzymes regulating dTTP pools were genotyped and their 
association with the development of sensory neuropathy in individuals on a d4T-
containing regimen was investigated. We further investigated the association of the 
SNPs with CD4+ T cell count and mtDNA copy number. To achieve these aims we 
selected 26 SNPs from the ADME genes and the SNPs were genotyped with the 
Sequenom assay followed by statistical associations with the phenotypes (sensory 
neuropathy, CD4+ T cell count, mtDNA copy number).  
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mtDNA copy number was investigated as an indicator of mtDNA toxicity, and a qPCR 
assay was used to compare mtDNA copy number  in individuals with SN and without 
SN after d4T-use.  
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4.1 Genetic variation in ADME genes in the black SA population  
 
Our reports of MAF for these SNPs in the black South African populations are novel.  
The MTHFR alleles C677T (rs1801133) and A1298C (rs1801133) have been reported 
in the SA populations. The MTHFR allele C677T (rs1801133) was reported at a 
frequency of 0.07 in the sub-Saharan Africa (Rosenberg et al., 2002). In this study the 
MTHFR 677T (rs1801133) polymorphism also had the same allele frequency of 0.07. 
Allele frequencies in our SA cohort were often but not always similar to those reported 
in the YRI and LWK populations. Scholtz et al. (2002) reported that the polymorphisms 
C677T and A1298C were less common in the black population at frequencies (0.04 
and 0.09) respectively.  
 
There were five polymorphisms in drug transporter genes that were significantly 
different when compared between the three populations (SA vs. LWK vs. YRI). The 
polymorphisms rs2725252, rs12505410 and rs3114018 of the ABCG2 gene had 
relatively different minor allele frequencies compared to the YRI and LWK at p-values; 
p = 0.002, p = 0.04, p = 0.04 respectively. The rs2242046 SNP of the SLC28A1 is 
monomorphic in YRI; it was polymorphic in SA with MAF of 0.025 whereas in the LWK 
population MAF was 0.061, hence there was a significant difference amongst the three 
population groups (p = 0.0008).  The rs7853758 SNP of the SLC28A3 with the highest 
frequency of 0.50 in SA was significantly different to MAF observed in the LWK and 
YRI (p = 0.0001). These differences indicate that the Nigerian or Kenyan populations 
are not always good proxies for South African genetic data, as others have also shown 
(e.g. May et al. 2013). This observation warrants the establishment of a Southern 
African specific genomic data set. 
 
All the SNPs in all genes in cases and in controls were in Hardy-Weinberg equilibrium. 
Our data was used to construct haplotypes in seven genes and 42 haplotypes were 
constructed. We explored LD patterns using 21 SNPs spread across seven genes, we 
used confidence bounds to define a strong LD (D’ is greater than 0.98) (Gabriel et al., 
2002).  
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4.2. Demographic factors associated with phenotypes (SN, mtDNA copy 
number and CD4+ T cell count after ART).  
 
The incidence and prevalence of HIV-SN has increased in the post-ART era, 
suggesting that the use of ARTs, particularly NRTI use is a risk for developing sensory 
neuropathy (Wadley et al., 2011). Evans et al. (2011) reported that ATN is the most 
common toxicity of ART therapy in the sub-Saharan African. In the current study we 
evaluated the difference between the participants with SN and those without, in order 
to determine the characteristics which are independently associated with SN.  
 
Out of the demographic and clinical variables evaluated age and height were 
significantly associated with SN, while the other characteristics .i.e. BMI, weight, CD4+ 
T cell count at sampling, CD4+ T cell count (nadir), months HIV+, were not associated 
with SN. We found no demographic or clinical variable that associated with mtDNA 
copy number. Oshinaike et al. (2012) also reported that age was independently 
associated with SN, before and after the use of HAART, using a Nigerian cohort 
attending the HIV clinic in Lagos state University teaching hospital. Several studies of 
Han Chinese and African populations also found age and height independently 
associated with SN (Cheng et al., 1999; Wadley et al., 2011; Kamerman et al., 2012). 
Age as a risk factor for SN is as a result of diminished activity of peripheral nerves 
which occurs naturally due to aging , during the stages of SN the degeneration of small 
and larger nerve fibres is length-dependent making taller individuals suffer the most 
(Oshinaike et al., 2012).  
 
The number of months that participants had been HIV positive was significantly 
associated with CD4+ T cell count after ART (at sampling). CD4+ T cell count at 
sampling was not significantly associated with lowest CD4+ count before treatment 
initiation, age, height, weight, or BMI. Lawn et al. (2006) reported that advanced pre-
treatment immunodeficiency characterised by a low CD4+, was associated with 
immune restitution even after the initiation of ART. However nadir CD4 count in our 
cohort was not associated with CD4+ T cell count at sampling.  This could possibly be 
because our cohort was cross-sectional, all at different stages since ART initiation 
Gazzola et al. (2009) reported that old age was associated with CD4 count recovery, 
which is contrary to what we found in our study. 
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4.3 Associations between SNPs and sensory neuropathy 
 
The univariate analysis conducted revealed that, the SLC28A1 709C>A rs8187758 
and SAMHD1 haplotype rs8124728-rs1291142-rs1891643 GGA were associated with 
sensory neuropathy after ART use in a genotypic (co-dominant) model. However these 
associations were not significant after adjustment for multiple testing. In multivariate 
analyses taking into account height and age, MTHFR rs1801131, RRM2B rs16918482 
and SAMHD1 rs8124728 and rs1891643 were associated with SN after ART use, but 
again were not significant after correction for multiple testing. We therefore did not find 
any single SNP that was significantly associated with occurrence of SN after d4T use; 
these results were similar to GWAS results by Leger et al. (2014) who suggested that 
susceptibility to d4T -associated SN may not be explained by a single genetic variant 
with a marked effect.  
 
SLC28A1 is a concentrative nucleoside transport which transports nucleosides and 
nucleoside analogues such as d4T into the epithelial cells of the renal tubule, the 
apical (brush-border) of the small intestines etc. (Kis et al. 2010).  In the current study, 
the 709C>A (rs8187758) variant may have a role in SN, whereby carriers of the A 
allele of this SNP in co-dominance were slightly more (but not significant) susceptible 
to stavudine-induced neurotoxicity (PEMP1 = 0.026; OR= 0.731). rs8187758 is a 
missense variant (Q237K)  in SLC28A1 which has been reported to increase thymidine 
uptake (Szöke et al., 2009).   If this mutation increases d4T uptake relative to 
thymidine, this could underlie our observation of weak association with SN. Further 
functional characterization is necessary in order to have a clear understanding of the 
effects of the polymorphism in SN. The 709C>A (rs8187758) polymorphism was not 
associated with gemcitabine toxicity, a chemotherapeutic drug in a study investigating 
SNP association with tumour progression (Woo et al., 2012). 
 
The SAMHD1 gene belongs to the family of nucleases and phosphohydrolases that 
are distinguished by the presence of the HD domain (Gramberg et al., 2013). SAMHD1 
degrades dNTPs and mediates HIV-1 restriction by decreasing the concentration of 
the cellular dNTP pool (Lahouassa et al. 2012).  
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SAMHD1 deficient myeloid cells from a patient suffering from Aicardi-Goutières 
syndromes have shown to be susceptible to HIV suggesting that SAMHD1 prevents 
HIV infection in the myeloid cells (Coon et al., 2012). However variation in the 
SAMHD1 gene was shown not to influence HIV susceptibility in Europeans and 
African-Americans (Coon et al. 2012). SAMHD1 dephosphorylates dTTP but not d4T 
(Ballana et al. 2014). Increased expression of SAMHD1 could potentially decrease the 
dTTP pool but not the d4T-TP pool; this relative increase in d4T-TP could perhaps 
increase ART efficacy and also increase ART side effects such as SN.   
 
Decreased expression of SAMHD1 could therefore decrease ART efficacy and also 
decrease ART side effects such as SN. In the current study, one SAMHD1 haplotype 
(rs8124728-rs1291142-rs1891643 GGA) and two individual SNPs (rs8124728 and 
rs1891643) in SAMHD1 were associated with SN in univariate and multivariate 
analyses respectively, but these associations were not significant after correction for 
multiple testing.  The rs1291142 A allele is reported to decrease the mRNA levels of 
the SAMHD1 protein (Coon et al., 2012), whereas the functional role of the other two 
polymorphisms has not been determined yet.   
 
The enzyme MTHFR catalyses the conversion of 5, 10 methylene-tetrahydrofolate to 
5-methylene-tetrafolate and it generates methyl residues for the thymidylate synthase 
(TS) function (Domingo et al., 2011). The MTHFR 1298A→C (rs1801131) allele 
changes a glutamate to an alanine at position 429 of the codon (Glu429Ala) and leads 
to a decreased enzyme activity (Domingo et al., 2013).  The activity of the MTHFR 
enzyme has a direct impact on the function TS (Domingo et al., 2011).  
 
Domingo et al. (2013a) reported that the MTHFR gene that is devoid of polymorphisms 
displays a high enzyme activity which favours the formation of the 5, 10-methylene 
tetrahydrofolate which will consequently promote the creation of the inhibitory ternary 
complex involving TS, 5, 10-methylene tetrahydrofolate and deoxyuridine 
monophosphate. This inhibitory ternary complex will consequently lead to a decreased 
activity of TS which may reduce the intracellular dTTP levels and ultimately d4T-TP 
will have a competitive advantage (Domingo et al., 2013a).   Increased d4T-TP 
intracellular as a result of low TS expression and high MTHFR activity is associated 
with SN. 
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In the current study this SNP was related to SN in multivariate analysis but was not 
significant after correction for multiple testing.  Our findings were similar to those by 
Domingo et al. (2013a) since Domingo et al. (2013a) also found that the MTHFR gene 
polymorphisms rs1801131 was not independently associated with lipodystrophy, 
pancreatitis or peripheral neuropathy in Caucasian patients after d4T use. 
 
The MTHFR C677T rs1801133 allele converts alanine to a valine at position 222 of 
the codon (Ala222Val) and is associated with the increase in the enzyme’s heat-
vulnerability which reduces its specific activity (Rosenberg et al., 2002). Decreased 
MTHFR function leads to increased function of TS and as a result the dTTP 
intracellular levels will be elevated and therefore d4T-TP levels will not have a 
competitive advantage, and subsequently reduces the risk of mtDNA toxicity or SN. 
We did not find an association between this SNP rs1801133 and SN. These results 
were also similar to those by Domingo et al. (2013a) who also found that the MTHFR 
gene polymorphism rs1801133 was not independently associated with either 
pancreatitis or peripheral neuropathy in Caucasian patients after d4T use. However 
Domingo et al. (2013b) found that combinations of MTHFR SNPs rs1801131 or 
rs1801133 with TYMS SNPs contributed to d4T-induced lipodystrophy in Caucasians 
and this therefore deserves further study in a South African context. 
 
Ribonucleotide reductase (RNR) is the key enzyme that catalyses the de novo 
formation of deoxyribonucleotides from ribonucleotides. The RRM1 gene encodes the 
larger RNR1 subunit, while RRM2B encodes the small p53–inducible RNR2 subunit 
(also called p53R2). Several studies have shown that genetic variation in RRM1 is 
associated with toxicity of gemcitabine, a cytosine analog used in cancer treatment 
(Bepler et al. 2002; Sun et al. 2006; Dong et al. 2010).  Genetic variation in RRM2B 
has been shown to influence mtDNA copy number (Bourdon et al., 2007; Kimura et 
al., 2003; Tyynismaa et al., 2009).  
 
In the current study the rs16918482 polymorphism of the RRM2B gene was related to 
SN in multivariate analysis but was not significant after correction for multiple testing. 
The function of the 3’UTR variant is unknown, but its position in the promoter region 
suggests that it could possible influence SN by changing RRM2B expression. This 
hypothesis would need to be tested.   
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4.4 Associations between mtDNA copy number and sensory neuropathy.  
 
MtDNA depletion is regarded as the cornerstone of clinical NRTI toxicity, with the 
measurement of the mtDNA used as a surrogate to diagnose mitochondrial toxicities 
in tissues (Hosseini et al., 2007). DNA polymerase gamma (POLG/Pol-γ) is part of the 
enzymes and proteins responsible for mtDNA replication and is inhibited by NRTIs 
(Lewis et al., 2003; Selvaraj et al., 2014).It has been demonstrated that the depletion 
of the mtDNA is as a result of the inhibition of POLG by the NRTIs, however studies 
have not been able to categorically establish the link between NRTIs and the loss of 
mtDNA content, which implies that other secondary factors also play an effective role 
of causing SN    (Selvaraj et al., 2014). The mtDNA/nDNA ratios of cases (with SN) 
were compared with those of controls (without SN).  
 
Dalakas et al. (2001) showed that mtDNA copy number was depleted in nerve cells 
during ART- induced SN. While the gold standard for the diagnosis of ART - related 
mitochondrial toxic effects is muscle, fat or liver biopsy, this is not practical for routine 
screening and monitoring (Côté et al., 2002) and the detection of mtDNA changes in 
blood samples would be preferable. Kampira et al. (2014) found significantly lowered 
mtDNA copy number in whole blood samples in association with ART- induced SN 
and lactatemia. Cherry et al. (2002) showed that ART-induced lactatemia was 
associated with decreased mtDNA copy number in adipose tissue but not in PBMCs. 
 
In the current study, there were no significant differences in mtDNA copy number in 
whole blood samples from South African patients with or without SN after d4T use.  
The diagnosis of SN in this study differed from the one in Kampira et al. (2014), which 
might be the reason for the contradicting results. Results obtained in the current study 
were similar to those by Cherry et al. (2002).  Urata et al. (2008) observed that mtDNA 
copy number in PBMCs varied due to platelet contamination and this caused 
overestimation of mtDNA content.  Therefore, measurement of mtDNA copy number 
in whole blood samples which includes platelets (as done in this study), may not be 
very accurate. 
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4.5 Associations between SNPs and mtDNA copy number 
 
All the polymorphisms in the d4T transporter genes and dNTP pool regulator genes 
were not significantly associated with mtDNA copy number, in the univariate analysis 
and Taken together with the lack of variation of mtDNA copy number in cases and 
controls described above, this indicates that these SNPs were not mediating SN via 
the mechanism of mitochondrial toxicity. 
4.6 Associations between SNPs and CD4 + T cell count 
 
There is substantial amount of inter-individual differences observed in terms of CD4+ 
T cell count restitution after initiating ART (Grady et al., 2011). Variation in mtDNA, 
HLA, IL10 and IL7R genes has been shown to influence CD4+ T cell recovery after 
ART (Grady et al., 2011; Kampira et al., 2013; Kampira et al., 2014; Naicker et al., 
2015; Haralambieva et al., 2014; Chopera et al., 2017).   The influence of variation in  
drug transporter ABCB1 (MDR1) on CD4+ T cell count after ART has been 
inconsistent, with Fellay et al. (2002) and Parathyras et al. (2009) showing that 
variants in ABCB1 associated with immunological recovery after ART, whereas Nasi 
et al. (2003) and Winzer et al. (2005) did not find similar results.  
 
Few other ADME genes have been examined in the context of CD4+ T cell count 
recovery after ART. We investigated the effect of variation in genes encoding d4T 
transporters, and genes influencing thymidine metabolism, on CD4+ T cell count after 
d4T-ART in this cohort. 
 
During univariate analysis, five SNPs and seven haplotypes in the ABCG2, SLC28A1, 
SLC28A3 and TK2 genes were associated with CD4+ T cell count after ART use.  The 
SLC28A1 SNP rs81877158 and one haplotype in ABCG2 (rs12505410-rs2725252-
rs3114018 TAC) remained significantly associated with CD4+ T cell count after 
correction for multiple testing. In multivariate analyses taking into account months 
since HIV diagnosis, four SNPs and the same seven haplotypes were associated with 
CD4+ T cell count after ART use, but were not significant after correction for multiple 
testing. 
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The SLC28A1 SNP rs81877158 was discussed in the previous section.   We found 
that it was associated with increased CD4+ T cell count.  It was the only SNP in the 
current study that survived corrections for multiple testing and had potential roles in 
both SN and CD4+ T cell counts after ART use. This SNP was not associated with 
changes in mtDNA  copy number and therefore would not mediate CD4 / SN  
phenotypes by the mechanism of mitochondrial toxicity, As mentioned, rs8187758 is 
a missense variant (Q237K) which has been reported to increase thymidine uptake  of 
the SLC28A1 transporter protein (Szöke et al., 2009). It is not known if d4T uptake is 
also changed by this mutation.  Elevated intracellular levels of d4T-TP will reinforce 
the ability of antiviral drug to inhibit HIV-1 viral replication and as a result diminish HIV-
1 viral the improved drug efficacy will consequently enable the increase of CD4+ T 
cells and therefore immune restoration. Further functional characterization is 
necessary in order to have a clear understanding of the effects of the polymorphism 
on CD4+ T cell count changes. 
 
The BCRP transporter, encoded by the ABCG2 gene, is widely expressed in the liver, 
gastrointestinal tract and is involved in the efflux of clinically used drugs (Delord et al., 
2013). This efflux transporter of nucleosides may have a protective role against 
adverse drug events such as mtDNA toxicity by eliminating toxic substances and 
metabolites across the apical membrane and preventing their intracellular 
accumulation (Maekawa et al., 2006).  Increased efflux activity could cause decreased 
intracellular  ARV amounts and therefore decreased ART efficacy (e.g. lower CD4 
count), or decreased ART-induced toxicity, whereas decreased efflux activity could 
cause  increased intracellular  ARV amounts and therefore increased ART efficacy or 
increased toxicity. 
 
In this study the rs12505410|rs2725252|rs3114018 TAC haplotype in ABCG2 was 
associated with increased CD4+ T cell count and this remained significant after 
correction for multiple testing.  Three other haplotypes in ABCG2 
(rs2725252|rs3114018|rs2622604 CAT, ACC and CAC) were associated with 
increased CD4+ T cell count but did not remain significant after correction for multiple 
testing.  In addition, the single ABCG2 SNP rs2725252 was associated with increased 
CD4+ T cell count in univariate and multivariate analysis (PEMP<0.05), but this was 
not significant after correction for multiple testing. 
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The functions of the ABCG2 SNPs rs12505410, rs2725252, and rs3114018 are 
associated with changes in mRNA expression, the functionality of these SNPs is 
sparsely reported on and therefore it remains ambiguous as to whether the changes 
in mRNA expression are elevated or reduced. In addition, rs3114018 (C to A) has 
been associated with oxaliplatin-induced peripheral neuropathy in the Caucasian 
population of Spain (Custodio et al., 2014), suggesting a potential role for this SNP in 
decreased drug efflux. The rs12505410 - rs2725252 GG haplotype has been 
associated with response to imatinib during treatment of chronic myelogenous 
leukaemia (Delord et al. 2013).   
 
Delord et al. (2010) discovered that the ABCG2,19-744G>T (rs2725252) 
polymorphism was associated with the response of the 400 mg/d arm imatinib, a drug 
used for the treatment of chronic myelogenous leukaemia (CLM) together with two 
other ABCG2 polymorphisms (rs12505410 and rs13120400) in a Saint Louis 
exploratory cohort, Paris. We hypothesize that the ABCG2 haplotype 
rs12505410|rs2725252|rs3114018 TAC is associated with decreased ABCG2 
function, and therefore decreased ARV efflux, resulting in increased intracellular levels 
of d4T-TP and consequently good CD4+ count response. This hypothesis would need 
to be tested using functional assays. 
 
Transporter protein CNT3 encoded by the SLC28A3 gene facilitates d4T influx into 
cells (Molina-Arcas, Casado and Pastor-Anglada, 2009).  In this study the rs4877847 
SNP was associated with decreased CD4+ T cell count in both univariate and 
multivariate analyses but was not significant after correction for multiple testing. In 
addition one haplotype (rs7853758-rs4877847 AC) was associated with decreased 
CD4+ T cell count but was not significant after correction for multiple testing.   
 
The rs4877847 SNP has been reported to cause loss of function of the influx 
transporter (Visscher et al. 2011).  The 1502A>C (rs4877847) polymorphism was also 
revealed to be associated with a protective effect in anthracycline-induced 
cardiotoxicity in a cohort of Canadian descent (Visscher et al., 2013).   If this SNP 
causes decreased SLC28A3-mediated influx of d4T, this could potentially cause 
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decreased intracellular concentrations of ARV and therefore decreased CD4 counts. 
This hypothesis would need to be tested using functional assays. 
 
The TK2 gene is expressed ubiquitously in mitochondria and is responsible for the 
phosphorylation of deoxythymidine and deoxycytidine contributing in the salvage 
pathway of deoxynucleotide synthesis in the mitochondria (Oskoui et al., 2006). The 
initial phosphorylation of NRTIs is very important for both their pharmacological 
functional and mitochondrial toxicity (Hosseini et al., 2007).  Mutations in TK2 have 
been associated with autosomal recessive mitochondrial DNA depletion syndrome-2 
(MTDPS2), mitochondrial myopathy and progressive external ophthalmoplegia (PEO) 
(e.g. Saada et al., 2001; Behin et al., 2012).  
 
In this study the rs2288399 SNP was associated with decreased CD4+ T cell count in 
univariate analyses but was not significant after correction for multiple testing. This 
SNP is an intron variant with unknown function and few studies have previously 
examined this SNP. It was chosen in this study because it tags many (23) other SNPs 
in TK2 and was present in 15% of the SA cohort based on our results.  
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4.7. Strengths and weaknesses of the study 
 
4.7.1 Strengths  
The study examined polymorphisms that have never been studied before in the 
Southern African population, it has revealed very interesting findings one of them 
being that, the Southern African population is different to the other African populations 
on certain SNPs and a genomic data set specific for the southern African population 
is necessary.  Few studies looked at ADME genetics underlying CD4+ T cell response, 
which is critical because the sub-Saharan Africa has the highest number of people 
living with HIV and on ART.  
 
4.7.2 Weaknesses  
 
This study had the following weaknesses worth noting. The clinical information 
presented was only retrospective for a single time-point and no prospective clinical 
data was attained with respect to measures such as CD4+ count, viral load, treatment 
ability and peripheral pain.  The phenotypic data available were extremely limited, and 
did not include other measures of mitochondrial toxicity such as lactate levels or 
measures of lipodystrophy. SN cases and controls were not matched with regards to 
age and height, but these factors were taken into account in multivariate analysis.   
 
The DNA was the only sample we had; we did not have other samples like the plasma 
to check the dug levels of ART or cells for measuring gene expression. Samples of 
various types should be collected in future in order to perform functional assays. The 
YRI and LWK are not always good proxies for genetic data in SA populations and 
therefore reliance of these populations as a reference for the SA population does not 
always good results.  
 
This study examined only 26 SNPs; whole gene sequences or whole genome SNP 
approaches would be preferable.  Gene- gene and gene-environment interactions 
could also be analyzed, Due to the limitations of the current study, a replication study 
investigating the same polymorphisms can be carried out in a similar ART treated 
patient cohort in SA and other populations to confirm and validate our findings.  
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 The replacement of d4T by tenofovir in current SA ART regimens may mean that the 
current findings may no longer be relevant to clinical practice.   
 
Conclusion  
 
Identifying predictors of response to ART in South Africa is a priority since > 3 million 
people are using ART in this country in 2016.  In particular, human genetic variation 
could influence SN development or CD4+ T cell recovery after ART via the ADME 
genes which control drug absorption, distribution, metabolism and excretion / 
elimination. Our study took a candidate gene system approach which investigated 
variation in  genes that transport stavudine and genes that modulate the levels of 
dNTPs in the cell, and  examining their association with SN, with mitochondrial toxicity 
as measured by mtDNA:nDNA ratio, and with CD4+ T cell count after ART initiation in 
a South African cohort using d4T-ART.  
 
We determined allele frequencies for 26 SNPs in seven ADME genes that could form 
a basis for future studies in pharmacogenetic applications in South African 
populations.  We showed that allele frequencies in South Africans are not always the 
same as those in the often-used proxy Kenya and Nigerian populations.  
 
We confirmed that in this cohort, age and height were significantly associated with SN 
after d4T use, and that time since HIV diagnosis / ART initiation was significantly 
associated with post-ART CD4 count. This study identified no significant associations 
between 26 SNPs and SN, or between the 26 SNPs and mtDNA copy number. We 
also found no association between mtDNA copy measured in DNA extracted from 
whole blood, and SN.  
 
We found that the SLC28A1 SNP rs8187758 and an ABCG2 haplotype were 
significantly associated with the CD4+ T cell count after stavudine use.  This finding 
proposes a potential predictor of ART drug response in South Africans which may be 
used to help formulate drug doses that will be optimal for personalized treatment. 
These SNPs should be examined in South Africans using more current (tenofovir-
based) ART regimens to determine whether testing for these SNPs may still be useful. 
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APPENDIX B: GENOTYPE FREQUENCIES OF SA POPULATION. 
 
Chra 
 
SNP ID Genotypes Genotypic 
SN-free 
Genotypic 
SN 
Genotypic 
frequency 
(All) 
HWE (All) 
p-value 
d4T transporters 
3 rs3749442 AA 0.0183 0.0522 0.0370 0.697 
AG 0.3303            0.3507    0.3416 
GG 0.6514 0.5970 0.6214 
4 rs2725252 AA 0.0367 0.0299 0.0329 0.837 
AC 0.3211             0.3209    0.321 
CC 0.6422 0.6492 0.6461 
4 rs2622604 TT 0.0185 0.0229 0.0209 0.575 
TC 0.2037 0.2366    0.2218 
CC 0.7778 0.7405 0.7573 
4 rs12505410 GG 0.0093 0.0149 0.0124 1.000 
GT 0.1776 0.2537    0.2199 
TT 0.8131 0.7313 0.7676 
4 rs3114018 CC 0.1354 0.1832 0.1630 0.497 
CA 0.5104 0.5115    0.511 
AA 0.3542 0.3053 0.3260 
9 rs4877847 CC 0.2037 0.2313 0.2190 1.000 
CA 0.5463             0.4627    0.5 
AA 0.25 0.3060 0.2810 
9 rs7853758 AA 0.2385 0.0379 0.2428 0.701 
AG 0.5046    0.5224    0.5144 
GG 0.2569 0.7652 0.2428 
15 rs2242046 AA 0.000 0.000 0.000 0.575 
AG 0.0280   0.06716   0.0498 
GG 0.9720 0.9328 0.9502 
15 rs2290272 AA 0.046 0.05344 0.05 0.597 
AG 0.4495    0.3282    0.3833 
GG 0.5046 0.6183 0.5667 
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15 rs8187758 AA 0.0093 0.0379 0.0251 0.808 
AC 0.3364    0.197    0.2594 
CC 0.6542 0.7652 0.7155 
dNTP regulators 
1 rs1801131 
GG 0.02752 0.0075 0.0165 0.795 
GT 0.2752 0.2388    0.2551 
TT 0.6972 0.7537 0.7284 
1 rs1801133 
AA 0.0 0.0075 0.0041 1.000 
AG 0.1376 0.1269    0.1317 
GG 0.8624 0.8657 0.8642 
2 rs7574663 
GG 0.0092 0.0149 0.0082 0.680 
GC 0.1651 0.1418    0.1523 
CC 0.8257 0.8507 0.8395 
5 rs1650723 
TT 0.0 0.0 0.000 0.608 
TC 0.1284              0.1194    0.1235 
CC 0.8716 0.8806 0.8765 
8 rs16918482 
CC 0.0092 0.0075 0.0083 0.249 
CA 0.1193 0.1053    0.1116 
AA 0.8716 0.8806 0.8802 
11 rs1465952 
AA 0.2569 0.2331 0.2438 0.306 
AG 0.4495 0.4812    0.4669 
GG 0.2936 0.2857 0.2893 
11 rs11030918 
CC 0.0183 0.0526 0.037 1.000 
CT 0.3303 0.3233    0.3264 
TT 0.6514 0.6241 0.6364 
11 rs12806698 
AA 0.000 0.000 0.000 1.000 
AC 0.03704          0.0448   0.04132 
CC 0.9630 0.9552 0.9587 
11 rs1042927 
CC 0.0092 0.0149 0.0123 0.032 
CA 0.3578             0.3209    0.3374 
AA 0.6330 0.6642 0.6502 
16 rs3743712 GG 0.1667 0.1716 0.1694 0.281 
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GA 0.4815 0.4104    0.4421 
AA 0.3519 0.4179 0.3884 
16 rs11859474 
AA 0.0642 0.0970 0.0823 0.321 
AG 0.4037 0.3284    0.3621 
GG 0.4771 0.5746 0.5556 
16 rs2288399 
GG 0.0459 0.0299 0.0370 0.130 
GA 0.2202 0.2388     0.2305 
AA 0.7339 0.7313 0.7325 
20 rs8124728 
AA 0.0556 0.0149 0.0330 0.647 
AG 0.213 0.3209    0.2727 
GG 0.7315 0.6642 0.6942 
20 rs1291142 
GG 0.0459 0.0602 0.0537 1.000 
GA 0.4128 0.3083    0.3554 
AA 0.5413 0.6316 0.5885 
20 rs1891643 
GG 0.0183 0.0448 0.0329 1.000 
GA 0.3394 0.2836    0.3086 
AA 06422 0.6716 0.6584 
21 rs1051266 
CC 0.0734 0.0896 0.0823 0.369 
CT 0.4128 0.4925    0.4568 
TT 0.5138 0.4179 0.4609 
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APPENDIX C: MASS EXTEND EXTENSION PRIMERS. 
 
Locus PCR primer sequence Length Tm 
(°C) 
rs2622604_W1_F ACGTTGGATGACTCTGAAAGCACTGTTTTG 30 66.15 
rs2622604_W1_R ACGTTGGATGCATTTGAATGTCAGCTAGTC 30 65.92 
rs2725252_W1_F ACGTTGGATGTTAGCCAAGCAGTCAGGAAC 30 68.72 
rs2725252_W1_R ACGTTGGATGGCTGATTGAAGGTGCATAAC 30 67.58 
rs4877847_W2_F ACGTTGGATGGATCCCTGATGGACTTACAC 30 67.68 
rs4877847_W2_R ACGTTGGATGCCATGAGTAAGCCAGTCAAG 30 68.60 
rs2242046_W1_F ACGTTGGATGAGACCTCTCCAAGTACAAGC 30 67.76 
rs2242046_W1_R ACGTTGGATGACACTCACGGAGATCCACTG 31 69.46 
rs3114018_W1_F ACGTTGGATGGCCACTGAGGAAAAGACTTC 30 68.53 
rs3114018_W1_R ACGTTGGATGGGAAACCTCACAAAAGTGTC 30 67.41 
rs2290272_W2_F ACGTTGGATGTGAGCAACTGGTGTCCTTCG 30 70.27 
rs2290272_W2_R ACGTTGGATGCTGCGCAATGATGCTTTGAG 30 70.12 
rs3749442_W2_F ACGTTGGATGGGTTTGATCGTGAAGGATAC 30 66.78 
rs3749442_W2_R ACGTTGGATGTGACCTTTGAGAACGCAGAG 30 68.65 
rs1650723_W1_F ACGTTGGATGCCATGGAGATATATTGCCATC 31 66.83 
rs1650723_W1_R ACGTTGGATGCACTTGTTAATAAGTGCTGG 30 66.08 
rs1042927_W1_F ACGTTGGATGCAGGGAGTGGTTAAGTAAGG 30 68.00 
rs1042927_W1_R ACGTTGGATGTAGAGACCCACCAGTCAAAG 30 67.74 
rs8187758_W2_F ACGTTGGATGTACTTGGACTCCTCGTCATC 30 67.58 
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rs8187758_W2_R ACGTTGGATGCCAGACCCCACATACCTAC 30 69.42 
rs7853758_W1_ F ACGTTGGATGTCAGCTGTGGGTAGTCAAAC 30 68.48 
rs7853758_W1_ R ACGTTGGATGCCAACATCGCTGTGAATCTG 30 69.34 
rs1801131_W2_F ACGTTGGATGTCTCCCGAGAGGTAAAGAAC 30 67.56 
rs1801131_W2_R ACGTTGGATGTCTACCTGAAGAGCAAGTCC 30 67.76 
rs1801133_W2_F ACGTTGGATGGTGCATGCCTTCACAAAGCG 30 71.49 
rs1801133_W2_R ACGTTGGATGCACTTGAAGGAGAAGGTGTC 30 68.50 
rs12806698_W1_F ACGTTGGATGACTCAACATGGCGGCTACAC 30 70.35 
rs12806698_W1_R ACGTTGGATGAATGACGTTACTCGACGCTG 30 68.65 
rs12505410_W2_F ACGTTGGATGCCTTGGCACCTTAAATGAAC 30 67.93 
rs12505410_W2_R ACGTTGGATGCATGATTCAAACTTGGCCTC 30 67.96 
rs8124728_W1_F ACGTTGGATGCTCCAACTCTTTACCCCAAC 30 68.55 
rs8124728_W1_R ACGTTGGATGTCTGGCTCTACAGGGATGC 30 69.60 
rs1891643_W1_ F ACGTTGGATGCATTGTCAGTACTCCCTCAC 30 68.17 
rs1891643_W1_R ACGTTGATGGCAGGATAATGAATCACAGG 29 65.37 
rs3743712_W2_F ACGTTGGATGTCTGGCTCTACAGGGATGC 29 68.55 
rs3743712_W2_R ACGTTGGATGAGATGGCACATGGGCACAAC 30 69.60 
rs16918482_W2_F ACGTTGGATGCTTGGCAAACTGAAGCAATG 30 68.65 
rs16918482_W2_R ACGTTGGATGCAAAAGGAGCAGGCCATAAC 30 69.41 
rs1465952_W2_F ACGTTGGATGTCCTTTGCCCAGGGAAAATG 30 69.21 
rs1465952_W2_R ACGTTGGATGTTTATCTGGTAACCCTGCCC 30 68.26 
rs11030918_W1_F ACGTTGGATGACCATCCACTGAAGAACCCT 30 69.06 
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rs11030918_W1_R ACGTTGGATGTCCTGACGCAAATCAGAGCC 30 70.37 
rs7574663_W1_F ACGTTGGATGGCAAATGTAGAATGTGGGAC 30 67.37 
rs7574663_W1_R ACGTTGGATGCTTTTCCCCACGACATTGAC 30 69.30 
rs11859474_W2_F ACGTTGGATGTTACTCCAACCAGCGAGTGA 30 69.33 
rs11859474_W2_R ACGTTGGATGTTCGTGTCCTCATGCAGTTC 30 68.87 
rs1051266_W1_ F ACGTTGGATGTGAAGCCGTAGAAGCAAAGG 30 68.91 
rs1051266_W1_ R ACGTTGGATGAGAAGCAGGTGCCCGTGGAA 30 72.87 
rs1291142_W1_ F ACGTTGGATGAGCTCATTCCAGCTTCATGC 30 69.03 
rs1291142_W1_ R ACGTTGGATGGTGTTTGGATGAGTAGCAGG 30 68.39 
rs2288399_W1_ F ACGTTGGATGGAAGGACAGCTCAAGAAACC 30 68.53 
rs2288399_W1_ R ACGTTGGATGTCAGAGCCCTGTGATCATGC 30 70.07 
 
